[
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e002062.html",
    "subject": "Gene Therapy for Hemophilia",
    "document_number": "MED.00135",
    "publish_date": "05/16/2024",
    "status": "Revised",
    "last_review_date": "05/09/2024",
    "html_content": "<p style=\"margin-bottom:8px\"><strong>Medically Necessary:</strong></p>\n<p>Etranacogene dezaparvovec-drlb is considered <strong>medically necessary</strong> in individuals who meet <strong>all</strong> of the following criteria:</p>\n<li>Diagnosis of hemophilia B; <strong>and</strong></li>\n<li>Age 18 years or older; <strong>and</strong></li>\n<li>Baseline factor IX level is less than 1 international unit (IU)/deciliter (dL) (or 1% endogenous factor IX); <strong>and</strong></li>\n<li>No contraindications to infusion (if any of the following are present, treatment is contraindicated):\t<ol>\t\t<li>Active infection; <strong>or</strong></li>\t\t<li>Immunosuppressive disorder; <strong>or</strong></li>\t\t<li>Liver cirrhosis; <strong>or</strong></li>\t\t<li>Active hepatitis B or C; <strong>or</strong></li>\t\t<li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; <strong>or</strong></li>\t\t<li>Bilirubin greater than 3 times the upper limit of normal; <strong>or</strong></li>\t\t<li>Alkaline phosphatase greater than 3 times the upper limit of normal; <strong>or</strong></li>\t\t<li>International normalized ratio (INR) greater than1.4.; <strong>or</strong></li>\t\t<li>Prior infusion of gene therapy for hemophilia B (for example, etranacogene dezaparvovec-drlb or fidanacogene elaparvovec-dzkt);<br>\t\t<strong>and</strong></li>\t</ol>\t</li>\n<li>Active infection; <strong>or</strong></li>\n<li>Immunosuppressive disorder; <strong>or</strong></li>\n<li>Liver cirrhosis; <strong>or</strong></li>\n<li>Active hepatitis B or C; <strong>or</strong></li>\n<li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; <strong>or</strong></li>\n<li>Bilirubin greater than 3 times the upper limit of normal; <strong>or</strong></li>\n<li>Alkaline phosphatase greater than 3 times the upper limit of normal; <strong>or</strong></li>\n<li>International normalized ratio (INR) greater than1.4.; <strong>or</strong></li>\n<li>Prior infusion of gene therapy for hemophilia B (for example, etranacogene dezaparvovec-drlb or fidanacogene elaparvovec-dzkt);<br>\t\t<strong>and</strong></li>\n<li>Poor disease control meeting one or more of the following:\t<ol>\t\t<li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\t\t<li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\t\t<li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li>\t</ol>\t</li>\n<li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\n<li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\n<li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li>\n<p>Fidanacogene elaparvovec-dzkt is considered <strong>medically necessary</strong> in individuals who meet <strong>all</strong> of the following criteria:</p>\n<li>Diagnosis of hemophilia B; <strong>and</strong></li>\n<li>Age 18 years or older; <strong>and</strong></li>\n<li>Baseline factor IX level is less than 1 international unit (IU)/deciliter (dL) (or 1% endogenous factor IX); <strong>and</strong></li>\n<li>No contraindications to infusion (if any of the following are present, treatment is contraindicated):\t<ol>\t\t<li>Neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid; <strong>or</strong></li>\t\t<li>Active infection; <strong>or</strong></li>\t\t<li>Immunosuppressive disorder; <strong>or</strong></li>\t\t<li>Liver cirrhosis; <strong>or</strong></li>\t\t<li>Active hepatitis B or C; <strong>or</strong></li>\t\t<li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; <strong>or</strong></li>\t\t<li>Bilirubin greater than 3 times the upper limit of normal; <strong>or</strong></li>\t\t<li>Alkaline phosphatase greater than 3 times the upper limit of normal; <strong>or</strong></li>\t\t<li>International normalized ratio (INR) greater than1.4.; <strong>or</strong></li>\t\t<li>Prior infusion of gene therapy for hemophilia B (for example, etranacogene dezaparvovec-drlb or fidanacogene elaparvovec-dzkt);<br>\t\t<strong>and</strong></li>\t</ol>\t</li>\n<li>Neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid; <strong>or</strong></li>\n<li>Active infection; <strong>or</strong></li>\n<li>Immunosuppressive disorder; <strong>or</strong></li>\n<li>Liver cirrhosis; <strong>or</strong></li>\n<li>Active hepatitis B or C; <strong>or</strong></li>\n<li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; <strong>or</strong></li>\n<li>Bilirubin greater than 3 times the upper limit of normal; <strong>or</strong></li>\n<li>Alkaline phosphatase greater than 3 times the upper limit of normal; <strong>or</strong></li>\n<li>International normalized ratio (INR) greater than1.4.; <strong>or</strong></li>\n<li>Prior infusion of gene therapy for hemophilia B (for example, etranacogene dezaparvovec-drlb or fidanacogene elaparvovec-dzkt);<br>\t\t<strong>and</strong></li>\n<li>Poor disease control meeting one or more of the following:\t<ol>\t\t<li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\t\t<li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\t\t<li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li>\t</ol>\t</li>\n<li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\n<li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\n<li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li>\n<p>Valoctocogene roxaparvovec-rvox is considered <strong>medically necessary</strong> in individuals who meet <strong>all</strong> of the following criteria:</p>\n<li>Diagnosis of hemophilia A; <strong>and</strong></li>\n<li>Age 18 years or older; <strong>and</strong></li>\n<li>Baseline factor VIII level is less than 1 international unit (IU)/deciliter (dL) (or 1% endogenous factor VIII); <strong>and</strong></li>\n<li>No contraindications to infusion (if any of the following are present, treatment is contraindicated):\t<ol>\t\t<li>Detectable pre-existing immunity to the AAV5 capsid as measured by AAV5 transduction inhibition or AAV5 total antibodies; <strong>or</strong></li>\t\t<li>History of factor VIII inhibitor; <strong>or</strong></li>\t\t<li>Active infection; <strong>or</strong></li>\t\t<li>Immunosuppressive disorder; <strong>or</strong></li>\t\t<li>Liver cirrhosis; <strong>or</strong></li>\t\t<li>Active hepatitis B or C; <strong>or</strong></li>\t\t<li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; <strong>or</strong></li>\t\t<li>Bilirubin greater than 3 times the upper limit of normal; <strong>or</strong></li>\t\t<li>Alkaline phosphatase greater than 3 times the upper limit of normal; <strong>or</strong></li>\t\t<li>International normalized ratio (INR) greater than1.4.; <strong>or</strong></li>\t\t<li>Prior infusion of valoctocogene roxaparvovec-rvox;<br>\t\t<strong>and</strong></li>\t</ol>\t</li>\n<li>Detectable pre-existing immunity to the AAV5 capsid as measured by AAV5 transduction inhibition or AAV5 total antibodies; <strong>or</strong></li>\n<li>History of factor VIII inhibitor; <strong>or</strong></li>\n<li>Active infection; <strong>or</strong></li>\n<li>Immunosuppressive disorder; <strong>or</strong></li>\n<li>Liver cirrhosis; <strong>or</strong></li>\n<li>Active hepatitis B or C; <strong>or</strong></li>\n<li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; <strong>or</strong></li>\n<li>Bilirubin greater than 3 times the upper limit of normal; <strong>or</strong></li>\n<li>Alkaline phosphatase greater than 3 times the upper limit of normal; <strong>or</strong></li>\n<li>International normalized ratio (INR) greater than1.4.; <strong>or</strong></li>\n<li>Prior infusion of valoctocogene roxaparvovec-rvox;<br>\t\t<strong>and</strong></li>\n<li>Poor disease control meeting one or more of the following:\t<ol>\t\t<li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\t\t<li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\t\t<li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li>\t</ol>\t</li>\n<li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\n<li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; <strong>or</strong></li>\n<li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p style=\"margin-bottom:8px\">Gene therapy for hemophilia is considered <strong>investigational and not medically necessary</strong> when the criteria above are not met and in all other situations.</p>",
    "content": "Medically Necessary:\nEtranacogene dezaparvovec-drlb is considered medically necessary in individuals who meet all of the following criteria:\n<li>Diagnosis of hemophilia B; and</li>\n<li>Age 18 years or older; and</li>\n<li>Baseline factor IX level is less than 1 international unit (IU)/deciliter (dL) (or 1% endogenous factor IX); and</li>\n<li>No contraindications to infusion (if any of the following are present, treatment is contraindicated):\t<ol> <li>Active infection; or</li> <li>Immunosuppressive disorder; or</li> <li>Liver cirrhosis; or</li> <li>Active hepatitis B or C; or</li> <li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; or</li> <li>Bilirubin greater than 3 times the upper limit of normal; or</li> <li>Alkaline phosphatase greater than 3 times the upper limit of normal; or</li> <li>International normalized ratio (INR) greater than1.4.; or</li> <li>Prior infusion of gene therapy for hemophilia B (for example, etranacogene dezaparvovec-drlb or fidanacogene elaparvovec-dzkt);<br/> and</li> </ol> </li>\n<li>Active infection; or</li>\n<li>Immunosuppressive disorder; or</li>\n<li>Liver cirrhosis; or</li>\n<li>Active hepatitis B or C; or</li>\n<li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; or</li>\n<li>Bilirubin greater than 3 times the upper limit of normal; or</li>\n<li>Alkaline phosphatase greater than 3 times the upper limit of normal; or</li>\n<li>International normalized ratio (INR) greater than1.4.; or</li>\n<li>Prior infusion of gene therapy for hemophilia B (for example, etranacogene dezaparvovec-drlb or fidanacogene elaparvovec-dzkt);<br/> and</li>\n<li>Poor disease control meeting one or more of the following:\t<ol> <li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; or</li> <li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; or</li> <li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li> </ol> </li>\n<li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; or</li>\n<li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; or</li>\n<li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li>\nFidanacogene elaparvovec-dzkt is considered medically necessary in individuals who meet all of the following criteria:\n<li>Diagnosis of hemophilia B; and</li>\n<li>Age 18 years or older; and</li>\n<li>Baseline factor IX level is less than 1 international unit (IU)/deciliter (dL) (or 1% endogenous factor IX); and</li>\n<li>No contraindications to infusion (if any of the following are present, treatment is contraindicated):\t<ol> <li>Neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid; or</li> <li>Active infection; or</li> <li>Immunosuppressive disorder; or</li> <li>Liver cirrhosis; or</li> <li>Active hepatitis B or C; or</li> <li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; or</li> <li>Bilirubin greater than 3 times the upper limit of normal; or</li> <li>Alkaline phosphatase greater than 3 times the upper limit of normal; or</li> <li>International normalized ratio (INR) greater than1.4.; or</li> <li>Prior infusion of gene therapy for hemophilia B (for example, etranacogene dezaparvovec-drlb or fidanacogene elaparvovec-dzkt);<br/> and</li> </ol> </li>\n<li>Neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid; or</li>\n<li>Active infection; or</li>\n<li>Immunosuppressive disorder; or</li>\n<li>Liver cirrhosis; or</li>\n<li>Active hepatitis B or C; or</li>\n<li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; or</li>\n<li>Bilirubin greater than 3 times the upper limit of normal; or</li>\n<li>Alkaline phosphatase greater than 3 times the upper limit of normal; or</li>\n<li>International normalized ratio (INR) greater than1.4.; or</li>\n<li>Prior infusion of gene therapy for hemophilia B (for example, etranacogene dezaparvovec-drlb or fidanacogene elaparvovec-dzkt);<br/> and</li>\n<li>Poor disease control meeting one or more of the following:\t<ol> <li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; or</li> <li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; or</li> <li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li> </ol> </li>\n<li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; or</li>\n<li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; or</li>\n<li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li>\nValoctocogene roxaparvovec-rvox is considered medically necessary in individuals who meet all of the following criteria:\n<li>Diagnosis of hemophilia A; and</li>\n<li>Age 18 years or older; and</li>\n<li>Baseline factor VIII level is less than 1 international unit (IU)/deciliter (dL) (or 1% endogenous factor VIII); and</li>\n<li>No contraindications to infusion (if any of the following are present, treatment is contraindicated):\t<ol> <li>Detectable pre-existing immunity to the AAV5 capsid as measured by AAV5 transduction inhibition or AAV5 total antibodies; or</li> <li>History of factor VIII inhibitor; or</li> <li>Active infection; or</li> <li>Immunosuppressive disorder; or</li> <li>Liver cirrhosis; or</li> <li>Active hepatitis B or C; or</li> <li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; or</li> <li>Bilirubin greater than 3 times the upper limit of normal; or</li> <li>Alkaline phosphatase greater than 3 times the upper limit of normal; or</li> <li>International normalized ratio (INR) greater than1.4.; or</li> <li>Prior infusion of valoctocogene roxaparvovec-rvox;<br/> and</li> </ol> </li>\n<li>Detectable pre-existing immunity to the AAV5 capsid as measured by AAV5 transduction inhibition or AAV5 total antibodies; or</li>\n<li>History of factor VIII inhibitor; or</li>\n<li>Active infection; or</li>\n<li>Immunosuppressive disorder; or</li>\n<li>Liver cirrhosis; or</li>\n<li>Active hepatitis B or C; or</li>\n<li>Alanine transaminase (ALT) greater than 3 times the upper limit of normal; or</li>\n<li>Bilirubin greater than 3 times the upper limit of normal; or</li>\n<li>Alkaline phosphatase greater than 3 times the upper limit of normal; or</li>\n<li>International normalized ratio (INR) greater than1.4.; or</li>\n<li>Prior infusion of valoctocogene roxaparvovec-rvox;<br/> and</li>\n<li>Poor disease control meeting one or more of the following:\t<ol> <li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; or</li> <li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; or</li> <li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li> </ol> </li>\n<li>One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy; or</li>\n<li>Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy; or</li>\n<li>At least 12 bleeding episodes over the previous year while receiving on-demand therapy.</li>\nInvestigational and Not Medically Necessary:\nGene therapy for hemophilia is considered investigational and not medically necessary when the criteria above are not met and in all other situations.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Etranacogene dezaparvovec-drlb",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Etranacogene dezaparvovec-drlb is considered medically necessary in individuals who meet all of the following criteria:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Diagnosis of hemophilia B",
                  "conditions": null
                },
                {
                  "desc": "Age 18 years or older",
                  "conditions": null
                },
                {
                  "desc": "Baseline factor IX level is less than 1 international unit (IU)/deciliter (dL) (or 1% endogenous factor IX)",
                  "conditions": null
                },
                {
                  "desc": "No contraindications to infusion",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Active infection",
                        "conditions": null
                      },
                      {
                        "desc": "Immunosuppressive disorder",
                        "conditions": null
                      },
                      {
                        "desc": "Liver cirrhosis",
                        "conditions": null
                      },
                      {
                        "desc": "Active hepatitis B or C",
                        "conditions": null
                      },
                      {
                        "desc": "Alanine transaminase (ALT) greater than 3 times the upper limit of normal",
                        "conditions": null
                      },
                      {
                        "desc": "Bilirubin greater than 3 times the upper limit of normal",
                        "conditions": null
                      },
                      {
                        "desc": "Alkaline phosphatase greater than 3 times the upper limit of normal",
                        "conditions": null
                      },
                      {
                        "desc": "International normalized ratio (INR) greater than 1.4",
                        "conditions": null
                      },
                      {
                        "desc": "Prior infusion of gene therapy for hemophilia B (for example, etranacogene dezaparvovec-drlb or fidanacogene elaparvovec-dzkt)",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Poor disease control meeting one or more of the following",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy",
                        "conditions": null
                      },
                      {
                        "desc": "Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy",
                        "conditions": null
                      },
                      {
                        "desc": "At least 12 bleeding episodes over the previous year while receiving on-demand therapy",
                        "conditions": null
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "Fidanacogene elaparvovec-dzkt",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Fidanacogene elaparvovec-dzkt is considered medically necessary in individuals who meet all of the following criteria:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Diagnosis of hemophilia B",
                  "conditions": null
                },
                {
                  "desc": "Age 18 years or older",
                  "conditions": null
                },
                {
                  "desc": "Baseline factor IX level is less than 1 international unit (IU)/deciliter (dL) (or 1% endogenous factor IX)",
                  "conditions": null
                },
                {
                  "desc": "No contraindications to infusion",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid",
                        "conditions": null
                      },
                      {
                        "desc": "Active infection",
                        "conditions": null
                      },
                      {
                        "desc": "Immunosuppressive disorder",
                        "conditions": null
                      },
                      {
                        "desc": "Liver cirrhosis",
                        "conditions": null
                      },
                      {
                        "desc": "Active hepatitis B or C",
                        "conditions": null
                      },
                      {
                        "desc": "Alanine transaminase (ALT) greater than 3 times the upper limit of normal",
                        "conditions": null
                      },
                      {
                        "desc": "Bilirubin greater than 3 times the upper limit of normal",
                        "conditions": null
                      },
                      {
                        "desc": "Alkaline phosphatase greater than 3 times the upper limit of normal",
                        "conditions": null
                      },
                      {
                        "desc": "International normalized ratio (INR) greater than 1.4",
                        "conditions": null
                      },
                      {
                        "desc": "Prior infusion of gene therapy for hemophilia B (for example, etranacogene dezaparvovec-drlb or fidanacogene elaparvovec-dzkt)",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Poor disease control meeting one or more of the following",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy",
                        "conditions": null
                      },
                      {
                        "desc": "Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy",
                        "conditions": null
                      },
                      {
                        "desc": "At least 12 bleeding episodes over the previous year while receiving on-demand therapy",
                        "conditions": null
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "Valoctocogene roxaparvovec-rvox",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Valoctocogene roxaparvovec-rvox is considered medically necessary in individuals who meet all of the following criteria:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Diagnosis of hemophilia A",
                  "conditions": null
                },
                {
                  "desc": "Age 18 years or older",
                  "conditions": null
                },
                {
                  "desc": "Baseline factor VIII level is less than 1 international unit (IU)/deciliter (dL) (or 1% endogenous factor VIII)",
                  "conditions": null
                },
                {
                  "desc": "No contraindications to infusion",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Detectable pre-existing immunity to the AAV5 capsid as measured by AAV5 transduction inhibition or AAV5 total antibodies",
                        "conditions": null
                      },
                      {
                        "desc": "History of factor VIII inhibitor",
                        "conditions": null
                      },
                      {
                        "desc": "Active infection",
                        "conditions": null
                      },
                      {
                        "desc": "Immunosuppressive disorder",
                        "conditions": null
                      },
                      {
                        "desc": "Liver cirrhosis",
                        "conditions": null
                      },
                      {
                        "desc": "Active hepatitis B or C",
                        "conditions": null
                      },
                      {
                        "desc": "Alanine transaminase (ALT) greater than 3 times the upper limit of normal",
                        "conditions": null
                      },
                      {
                        "desc": "Bilirubin greater than 3 times the upper limit of normal",
                        "conditions": null
                      },
                      {
                        "desc": "Alkaline phosphatase greater than 3 times the upper limit of normal",
                        "conditions": null
                      },
                      {
                        "desc": "International normalized ratio (INR) greater than 1.4",
                        "conditions": null
                      },
                      {
                        "desc": "Prior infusion of valoctocogene roxaparvovec-rvox",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Poor disease control meeting one or more of the following",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "One or more episodes of spontaneous bleeding into a joint or the central nervous system while receiving routine prophylaxis factor replacement therapy",
                        "conditions": null
                      },
                      {
                        "desc": "Four or more episodes of soft tissue bleeding in an 8-week period while receiving routine prophylaxis factor replacement therapy",
                        "conditions": null
                      },
                      {
                        "desc": "At least 12 bleeding episodes over the previous year while receiving on-demand therapy",
                        "conditions": null
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "Gene therapy for hemophilia",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Gene therapy for hemophilia is considered investigational and not medically necessary when the criteria above are not met and in all other situations.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 4751,
          "prompt_tokens": 2961,
          "completion_tokens": 1790,
          "total_cost": 0.041655,
          "processing_time": 29.39889407157898
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e003052.html",
    "subject": "Gene Therapy for Metachromatic Leukodystrophy",
    "document_number": "MED.00148",
    "publish_date": "05/16/2024",
    "status": "New",
    "last_review_date": "05/09/2024",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>A one-time infusion of atidarsagene autotemcel is considered <strong>medically necessary</strong> in individuals who meet <strong>all</strong> of the following criteria:</p>\n<li>Diagnosis of metachromatic leukodystrophy (MLD); and</li>\n<li>Documentation of an arylsulfatase A (ARSA) genotype (biallelic ARSA pathogenic variant); <strong>and</strong></li>\n<li>One of the following forms of MLD:\t<ol>\t\t<li>Pre-symptomatic<sup>1</sup> late infantile MLD (children with expected disease onset at or before 30 months of age); o<strong>r</strong></li>\t\t<li>Pre-symptomatic<sup>1</sup> early juvenile MLD (children with expected disease onset at more than 30 months and less than 7 years of age); <strong>or</strong></li>\t\t<li>Early symptomatic<sup>2</sup> early juvenile MLD (children with disease onset at more than 30 months of age and less than 7 years of age): <strong>AND</strong></li>\t</ol>\t</li>\n<li>Pre-symptomatic<sup>1</sup> late infantile MLD (children with expected disease onset at or before 30 months of age); o<strong>r</strong></li>\n<li>Pre-symptomatic<sup>1</sup> early juvenile MLD (children with expected disease onset at more than 30 months and less than 7 years of age); <strong>or</strong></li>\n<li>Early symptomatic<sup>2</sup> early juvenile MLD (children with disease onset at more than 30 months of age and less than 7 years of age): <strong>AND</strong></li>\n<li>Biochemical diagnosis of MLD defined by the following:\t<ol>\t\t<li>Deficient ARSA enzyme activity in leukocytes; <strong>and</strong></li>\t\t<li>Elevated urinary excretion of sulfatides; <strong>and</strong></li>\t</ol>\t</li>\n<li>Deficient ARSA enzyme activity in leukocytes; <strong>and</strong></li>\n<li>Elevated urinary excretion of sulfatides; <strong>and</strong></li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor<sup>3</sup>; <strong>and</strong></li>\n<li>Alanine transferase (ALT) no more than 2 times upper limit of normal (ULN) or total bilirubin no more than 1.5 ULN; <strong>and</strong></li>\n<li>No serious concomitant illness (for example, active malignant neoplasia other than skin cancer, serious hematologic disorder, end-stage organ dysfunction, acute or chronic stable hepatitis B, immunodeficiency disorder, active tuberculosis); <strong>and</strong></li>\n<li>No prior gene therapy.</li>\n<p><sup>1 </sup>Pre-symptomatic status is defined as the absence of neurological signs and symptoms of MLD or physical exam findings limited to abnormal reflexes and/or clonus. Pre-symptomatic children may have abnormal reflexes or abnormalities on brain magnetic resonance imaging and/or nerve conduction tests not associated with functional impairment.<br><sup>2</sup>Early symptomatic status is defined as the ability to walk independently and an intelligence quotient (IQ) greater than or equal to 85.<br><sup>3</sup>Documentation that a suitable donor has not been identified, for example, a matched related donor or matched (HLA 8/8 or 7/8) unrelated donor.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p style=\"margin-bottom:8px\">Gene therapy for metachromatic leukodystrophy is considered <strong>investigational and not medically necessary</strong> when the criteria above are not met and in all other situations.</p>",
    "content": "Medically Necessary:\nA one-time infusion of atidarsagene autotemcel is considered medically necessary in individuals who meet all of the following criteria:\n<li>Diagnosis of metachromatic leukodystrophy (MLD); and</li>\n<li>Documentation of an arylsulfatase A (ARSA) genotype (biallelic ARSA pathogenic variant); and</li>\n<li>One of the following forms of MLD:\t<ol> <li>Pre-symptomatic<sup>1</sup> late infantile MLD (children with expected disease onset at or before 30 months of age); or</li> <li>Pre-symptomatic<sup>1</sup> early juvenile MLD (children with expected disease onset at more than 30 months and less than 7 years of age); or</li> <li>Early symptomatic<sup>2</sup> early juvenile MLD (children with disease onset at more than 30 months of age and less than 7 years of age): AND</li> </ol> </li>\n<li>Pre-symptomatic<sup>1</sup> late infantile MLD (children with expected disease onset at or before 30 months of age); or</li>\n<li>Pre-symptomatic<sup>1</sup> early juvenile MLD (children with expected disease onset at more than 30 months and less than 7 years of age); or</li>\n<li>Early symptomatic<sup>2</sup> early juvenile MLD (children with disease onset at more than 30 months of age and less than 7 years of age): AND</li>\n<li>Biochemical diagnosis of MLD defined by the following:\t<ol> <li>Deficient ARSA enzyme activity in leukocytes; and</li> <li>Elevated urinary excretion of sulfatides; and</li> </ol> </li>\n<li>Deficient ARSA enzyme activity in leukocytes; and</li>\n<li>Elevated urinary excretion of sulfatides; and</li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor<sup>3</sup>; and</li>\n<li>Alanine transferase (ALT) no more than 2 times upper limit of normal (ULN) or total bilirubin no more than 1.5 ULN; and</li>\n<li>No serious concomitant illness (for example, active malignant neoplasia other than skin cancer, serious hematologic disorder, end-stage organ dysfunction, acute or chronic stable hepatitis B, immunodeficiency disorder, active tuberculosis); and</li>\n<li>No prior gene therapy.</li>\n<sup>1 </sup>Pre-symptomatic status is defined as the absence of neurological signs and symptoms of MLD or physical exam findings limited to abnormal reflexes and/or clonus. Pre-symptomatic children may have abnormal reflexes or abnormalities on brain magnetic resonance imaging and/or nerve conduction tests not associated with functional impairment.<br/><sup>2</sup>Early symptomatic status is defined as the ability to walk independently and an intelligence quotient (IQ) greater than or equal to 85.<br/><sup>3</sup>Documentation that a suitable donor has not been identified, for example, a matched related donor or matched (HLA 8/8 or 7/8) unrelated donor.\nInvestigational and Not Medically Necessary:\nGene therapy for metachromatic leukodystrophy is considered investigational and not medically necessary when the criteria above are not met and in all other situations.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "One-time infusion of atidarsagene autotemcel",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A one-time infusion of atidarsagene autotemcel is considered medically necessary in individuals who meet all of the following criteria:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Diagnosis of metachromatic leukodystrophy (MLD)",
                  "conditions": null
                },
                {
                  "desc": "Documentation of an arylsulfatase A (ARSA) genotype (biallelic ARSA pathogenic variant)",
                  "conditions": null
                },
                {
                  "ANY": [
                    {
                      "desc": "Pre-symptomatic late infantile MLD (children with expected disease onset at or before 30 months of age)",
                      "conditions": null
                    },
                    {
                      "desc": "Pre-symptomatic early juvenile MLD (children with expected disease onset at more than 30 months and less than 7 years of age)",
                      "conditions": null
                    },
                    {
                      "desc": "Early symptomatic early juvenile MLD (children with disease onset at more than 30 months of age and less than 7 years of age)",
                      "conditions": null
                    }
                  ]
                },
                {
                  "ALL": [
                    {
                      "desc": "Deficient ARSA enzyme activity in leukocytes",
                      "conditions": null
                    },
                    {
                      "desc": "Elevated urinary excretion of sulfatides",
                      "conditions": null
                    }
                  ]
                },
                {
                  "desc": "The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor",
                  "conditions": null
                },
                {
                  "desc": "Alanine transferase (ALT) no more than 2 times upper limit of normal (ULN) or total bilirubin no more than 1.5 ULN",
                  "conditions": null
                },
                {
                  "desc": "No serious concomitant illness (for example, active malignant neoplasia other than skin cancer, serious hematologic disorder, end-stage organ dysfunction, acute or chronic stable hepatitis B, immunodeficiency disorder, active tuberculosis)",
                  "conditions": null
                },
                {
                  "desc": "No prior gene therapy",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Gene therapy for metachromatic leukodystrophy",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Gene therapy for metachromatic leukodystrophy is considered investigational and not medically necessary when the criteria above are not met and in all other situations.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 2139,
          "prompt_tokens": 1565,
          "completion_tokens": 574,
          "total_cost": 0.016434999999999998,
          "processing_time": 12.603247165679932
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c160708.html",
    "subject": "Autonomic Testing",
    "document_number": "MED.00112",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of autonomic nervous system function testing for sudomotor function using quantitative sudomotor axon reflex test (QSART), the thermoregulatory sweat test (TST), silastic sweat imprint, sympathetic skin response (SSR), quantitative direct and indirect reflex test of sudomotor function (QDIRT), or SudoScan are considered <strong>investigational and not medically necessary</strong> for all indications.</p>\n<p>The use of autonomic nervous system function testing for cardiovagal innervations is considered <strong>investigational and not medically necessary</strong> for all indications.</p>\n<p>The use of autonomic nervous system function testing for vasomotor adrenergic innervations is considered <strong>investigational and not medically necessary</strong> for all indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of autonomic nervous system function testing for sudomotor function using quantitative sudomotor axon reflex test (QSART), the thermoregulatory sweat test (TST), silastic sweat imprint, sympathetic skin response (SSR), quantitative direct and indirect reflex test of sudomotor function (QDIRT), or SudoScan are considered investigational and not medically necessary for all indications.\nThe use of autonomic nervous system function testing for cardiovagal innervations is considered investigational and not medically necessary for all indications.\nThe use of autonomic nervous system function testing for vasomotor adrenergic innervations is considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Autonomic Nervous System Function Testing for Sudomotor Function",
            "sub_medical_act": "Quantitative Sudomotor Axon Reflex Test (QSART)",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of autonomic nervous system function testing for sudomotor function using quantitative sudomotor axon reflex test (QSART) is considered investigational and not medically necessary for all indications.",
            "conditions": null
          },
          {
            "medical_act": "Autonomic Nervous System Function Testing for Sudomotor Function",
            "sub_medical_act": "Thermoregulatory Sweat Test (TST)",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of autonomic nervous system function testing for sudomotor function using thermoregulatory sweat test (TST) is considered investigational and not medically necessary for all indications.",
            "conditions": null
          },
          {
            "medical_act": "Autonomic Nervous System Function Testing for Sudomotor Function",
            "sub_medical_act": "Silastic Sweat Imprint",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of autonomic nervous system function testing for sudomotor function using silastic sweat imprint is considered investigational and not medically necessary for all indications.",
            "conditions": null
          },
          {
            "medical_act": "Autonomic Nervous System Function Testing for Sudomotor Function",
            "sub_medical_act": "Sympathetic Skin Response (SSR)",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of autonomic nervous system function testing for sudomotor function using sympathetic skin response (SSR) is considered investigational and not medically necessary for all indications.",
            "conditions": null
          },
          {
            "medical_act": "Autonomic Nervous System Function Testing for Sudomotor Function",
            "sub_medical_act": "Quantitative Direct and Indirect Reflex Test of Sudomotor Function (QDIRT)",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of autonomic nervous system function testing for sudomotor function using quantitative direct and indirect reflex test of sudomotor function (QDIRT) is considered investigational and not medically necessary for all indications.",
            "conditions": null
          },
          {
            "medical_act": "Autonomic Nervous System Function Testing for Sudomotor Function",
            "sub_medical_act": "SudoScan",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of autonomic nervous system function testing for sudomotor function using SudoScan is considered investigational and not medically necessary for all indications.",
            "conditions": null
          },
          {
            "medical_act": "Autonomic Nervous System Function Testing for Cardiovagal Innervations",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of autonomic nervous system function testing for cardiovagal innervations is considered investigational and not medically necessary for all indications.",
            "conditions": null
          },
          {
            "medical_act": "Autonomic Nervous System Function Testing for Vasomotor Adrenergic Innervations",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of autonomic nervous system function testing for vasomotor adrenergic innervations is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1759,
          "prompt_tokens": 961,
          "completion_tokens": 798,
          "total_cost": 0.016774999999999998,
          "processing_time": 20.519042015075684
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c123691.html",
    "subject": "Non-invasive Measurement of Advanced Glycation End Products (AGEs) in the Skin",
    "document_number": "MED.00104",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Non-invasive measurement of advanced glycation end products (AGEs) in the skin is considered <strong>investigational and not medically necessary</strong> for all indications, including but not limited to diabetes, renal failure, and cardiac disease.</p>",
    "content": "Investigational and Not Medically Necessary:\nNon-invasive measurement of advanced glycation end products (AGEs) in the skin is considered investigational and not medically necessary for all indications, including but not limited to diabetes, renal failure, and cardiac disease.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Non-invasive measurement of advanced glycation end products (AGEs) in the skin",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Non-invasive measurement of advanced glycation end products (AGEs) in the skin is considered investigational and not medically necessary for all indications, including but not limited to diabetes, renal failure, and cardiac disease.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 969,
          "prompt_tokens": 863,
          "completion_tokens": 106,
          "total_cost": 0.0059050000000000005,
          "processing_time": 2.5298051834106445
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c181185.html",
    "subject": "Continuous Monitoring of Intraocular Pressure",
    "document_number": "MED.00118",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of continuous monitoring of intraocular pressure is considered <strong>investigational and not medically necessary</strong> for all indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of continuous monitoring of intraocular pressure is considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "continuous monitoring of intraocular pressure",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of continuous monitoring of intraocular pressure is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 917,
          "prompt_tokens": 842,
          "completion_tokens": 75,
          "total_cost": 0.005335,
          "processing_time": 4.172951698303223
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c150993.html",
    "subject": "Intracardiac Ischemia Monitoring",
    "document_number": "MED.00111",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Intracardiac ischemia monitoring is considered <strong>investigational and not medically necessary</strong> for all indications including, but not limited to, detection of acute myocardial ischemic events.</p>",
    "content": "Investigational and Not Medically Necessary:\nIntracardiac ischemia monitoring is considered investigational and not medically necessary for all indications including, but not limited to, detection of acute myocardial ischemic events.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Intracardiac ischemia monitoring",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Intracardiac ischemia monitoring is considered investigational and not medically necessary for all indications including, but not limited to, detection of acute myocardial ischemic events.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 942,
          "prompt_tokens": 854,
          "completion_tokens": 88,
          "total_cost": 0.00559,
          "processing_time": 1.536121129989624
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c108950.html",
    "subject": "Ultrafiltration in Decompensated Heart Failure",
    "document_number": "MED.00102",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of ultrafiltration is considered <strong>investigational and not medically necessary</strong> for the treatment of heart failure.</p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of ultrafiltration is considered investigational and not medically necessary for the treatment of heart failure.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Ultrafiltration",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of ultrafiltration is considered investigational and not medically necessary for the treatment of heart failure.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 915,
          "prompt_tokens": 842,
          "completion_tokens": 73,
          "total_cost": 0.005305,
          "processing_time": 2.217298746109009
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_d070610.html",
    "subject": "Gene Therapy for Ocular Conditions",
    "document_number": "MED.00120",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>The use of voretigene neparvovec-rzyl is considered <strong>medically necessary</strong> in individuals who meet <em>all</em> of the following criteria:</p>\n<li>A diagnosis of retinal dystrophy due to confirmed <em>RPE65</em> mutation(s) in <em>both</em> alleles;<strong> and</strong></li>\n<li>At least 1 year of age; <strong>and</strong></li>\n<li>For each eye indicated for treatment, sufficient viable retinal cells as determined by non-invasive means, such as optical coherence tomography (OCT) and/or ophthalmoscopy as evidenced by <em>one</em> of the following:\t<ol start=\"1\" style=\"list-style-type:decimal\">\t\t<li>An area of retina within the posterior pole of greater than 100 \u00b5m thickness shown on OCT; <strong>or</strong></li>\t\t<li>Three or more disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; <strong>or</strong></li>\t\t<li>Remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent;<br>\t\t<strong>and</strong></li>\t</ol>\t</li>\n<li>An area of retina within the posterior pole of greater than 100 \u00b5m thickness shown on OCT; <strong>or</strong></li>\n<li>Three or more disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; <strong>or</strong></li>\n<li>Remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent;<br>\t\t<strong>and</strong></li>\n<li>For each eye indicated for treatment, have not had intraocular surgery within 6 months.</li>\n<p><strong>Note:</strong> Voretigene neparvovec-rzyl has not been adequately studied or in individuals who are pregnant or unwilling to use contraception for 4 months after treatment.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of voretigene neparvovec-rzyl is considered <strong>investigational and not medically necessary</strong> when the above criteria are not met.</p>\n<p>Repeat injections of voretigene neparvovec-rzyl in the same eye are considered <strong>investigational and not medically necessary</strong> in all cases.</p>\n<p>The use of all other gene replacement therapies to treat any ocular condition is considered <strong>investigational and not medically</strong> <strong>necessary.</strong></p>",
    "content": "Medically Necessary:\nThe use of voretigene neparvovec-rzyl is considered medically necessary in individuals who meet all of the following criteria:\n<li>A diagnosis of retinal dystrophy due to confirmed RPE65 mutation(s) in both alleles; and</li>\n<li>At least 1 year of age; and</li>\n<li>For each eye indicated for treatment, sufficient viable retinal cells as determined by non-invasive means, such as optical coherence tomography (OCT) and/or ophthalmoscopy as evidenced by one of the following:\t<ol start=\"1\" style=\"list-style-type:decimal\"> <li>An area of retina within the posterior pole of greater than 100 \u00b5m thickness shown on OCT; or</li> <li>Three or more disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; or</li> <li>Remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent;<br/> and</li> </ol> </li>\n<li>An area of retina within the posterior pole of greater than 100 \u00b5m thickness shown on OCT; or</li>\n<li>Three or more disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; or</li>\n<li>Remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent;<br/> and</li>\n<li>For each eye indicated for treatment, have not had intraocular surgery within 6 months.</li>\nNote: Voretigene neparvovec-rzyl has not been adequately studied or in individuals who are pregnant or unwilling to use contraception for 4 months after treatment.\nInvestigational and Not Medically Necessary:\nThe use of voretigene neparvovec-rzyl is considered investigational and not medically necessary when the above criteria are not met.\nRepeat injections of voretigene neparvovec-rzyl in the same eye are considered investigational and not medically necessary in all cases.\nThe use of all other gene replacement therapies to treat any ocular condition is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Voretigene neparvovec-rzyl",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "The use of voretigene neparvovec-rzyl is considered medically necessary in individuals who meet all of the following criteria:",
            "conditions": {
              "ALL": [
                {
                  "desc": "A diagnosis of retinal dystrophy due to confirmed RPE65 mutation(s) in both alleles",
                  "conditions": null
                },
                {
                  "desc": "At least 1 year of age",
                  "conditions": null
                },
                {
                  "desc": "For each eye indicated for treatment, sufficient viable retinal cells as determined by non-invasive means, such as optical coherence tomography (OCT) and/or ophthalmoscopy as evidenced by one of the following:",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "An area of retina within the posterior pole of greater than 100 \u00b5m thickness shown on OCT",
                        "conditions": null
                      },
                      {
                        "desc": "Three or more disc areas of retina without atrophy or pigmentary degeneration within the posterior pole",
                        "conditions": null
                      },
                      {
                        "desc": "Remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "For each eye indicated for treatment, have not had intraocular surgery within 6 months",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Voretigene neparvovec-rzyl",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of voretigene neparvovec-rzyl is considered investigational and not medically necessary when the above criteria are not met.",
            "conditions": null
          },
          {
            "medical_act": "Repeat injections of voretigene neparvovec-rzyl in the same eye",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Repeat injections of voretigene neparvovec-rzyl in the same eye are considered investigational and not medically necessary in all cases.",
            "conditions": null
          },
          {
            "medical_act": "All other gene replacement therapies to treat any ocular condition",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of all other gene replacement therapies to treat any ocular condition is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1847,
          "prompt_tokens": 1257,
          "completion_tokens": 590,
          "total_cost": 0.015135,
          "processing_time": 7.534372806549072
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a049947.html",
    "subject": "Sensory Stimulation for Brain-Injured Individuals in Coma or Vegetative State",
    "document_number": "MED.00011",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Sensory stimulation (also known as: coma stimulation sessions, coma arousal therapy, multisensory stimulation programs and coma care) for brain injured individuals in a coma or vegetative state is considered <strong>investigational and not medically necessary.</strong></p>",
    "content": "Investigational and Not Medically Necessary:\nSensory stimulation (also known as: coma stimulation sessions, coma arousal therapy, multisensory stimulation programs and coma care) for brain injured individuals in a coma or vegetative state is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Sensory stimulation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Sensory stimulation (also known as: coma stimulation sessions, coma arousal therapy, multisensory stimulation programs and coma care) for brain injured individuals in a coma or vegetative state is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 964,
          "prompt_tokens": 867,
          "completion_tokens": 97,
          "total_cost": 0.00579,
          "processing_time": 4.969178915023804
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c108050.html",
    "subject": "Physiologic Recording of Tremor using Accelerometer(s) and Gyroscope(s)",
    "document_number": "MED.00101",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of accelerometer/motion analysis testing devices is considered <strong>investigational and not</strong> <strong>medically necessary</strong> for all applications, including, but not limited to, the evaluation of tremors.</p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of accelerometer/motion analysis testing devices is considered investigational and not medically necessary for all applications, including, but not limited to, the evaluation of tremors.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Use of accelerometer/motion analysis testing devices",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of accelerometer/motion analysis testing devices is considered investigational and not medically necessary for all applications, including, but not limited to, the evaluation of tremors.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 948,
          "prompt_tokens": 856,
          "completion_tokens": 92,
          "total_cost": 0.00566,
          "processing_time": 2.5637881755828857
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a049923.html",
    "subject": "Noninvasive Imaging Technologies for the Evaluation of Skin Lesions",
    "document_number": "MED.00004",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Not Medically Necessary:</strong></p>\n<p>Dermatoscopy (also known as dermoscopy, epiluminescence microscopy [ELM], or digital epiluminescence microscopy [DELM], skin surface microscopy, skin videomicroscopy, or incidence light microscopy) using either direct inspection, digitization of images, or computer-assisted analysis is considered <strong>not medically necessary</strong> in all cases.</p>\n<p>Reflectance confocal microscopy for the evaluation of skin lesions is considered <strong>not medically necessary</strong> in all cases.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Whole body integumentary photography, including melanomagram, is considered <strong>investigational and not medically necessary</strong> in all cases.</p>\n<p>The following technologies are considered <strong>investigational and not medically necessary</strong> for the evaluation of skin lesions:</p>\n<li>Confocal scanning laser microscopy</li>\n<li>Electrical impedance spectroscopy</li>\n<li>Elastic scattering spectroscopy</li>\n<li>Molecular fluorescent imaging</li>\n<li>Multi-spectral image analysis</li>\n<li>Multiphoton laser scanning microscopy</li>\n<li>Optical coherence tomography</li>\n<li>Photoacoustic microscopy</li>\n<li>Quantitative infrared imaging</li>\n<li>Raman spectroscopy</li>\n<li>Ultrasonography</li>\n<li>Visual image analysis</li>",
    "content": "Not Medically Necessary:\nDermatoscopy (also known as dermoscopy, epiluminescence microscopy [ELM], or digital epiluminescence microscopy [DELM], skin surface microscopy, skin videomicroscopy, or incidence light microscopy) using either direct inspection, digitization of images, or computer-assisted analysis is considered not medically necessary in all cases.\nReflectance confocal microscopy for the evaluation of skin lesions is considered not medically necessary in all cases.\nInvestigational and Not Medically Necessary:\nWhole body integumentary photography, including melanomagram, is considered investigational and not medically necessary in all cases.\nThe following technologies are considered investigational and not medically necessary for the evaluation of skin lesions:\n<li>Confocal scanning laser microscopy</li>\n<li>Electrical impedance spectroscopy</li>\n<li>Elastic scattering spectroscopy</li>\n<li>Molecular fluorescent imaging</li>\n<li>Multi-spectral image analysis</li>\n<li>Multiphoton laser scanning microscopy</li>\n<li>Optical coherence tomography</li>\n<li>Photoacoustic microscopy</li>\n<li>Quantitative infrared imaging</li>\n<li>Raman spectroscopy</li>\n<li>Ultrasonography</li>\n<li>Visual image analysis</li>",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Dermatoscopy",
            "sub_medical_act": null,
            "necessity_type": "Not Medically Necessary",
            "description": "Dermatoscopy (also known as dermoscopy, epiluminescence microscopy [ELM], or digital epiluminescence microscopy [DELM], skin surface microscopy, skin videomicroscopy, or incidence light microscopy) using either direct inspection, digitization of images, or computer-assisted analysis is considered not medically necessary in all cases.",
            "conditions": null
          },
          {
            "medical_act": "Reflectance confocal microscopy",
            "sub_medical_act": null,
            "necessity_type": "Not Medically Necessary",
            "description": "Reflectance confocal microscopy for the evaluation of skin lesions is considered not medically necessary in all cases.",
            "conditions": null
          },
          {
            "medical_act": "Whole body integumentary photography",
            "sub_medical_act": "Melanomagram",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Whole body integumentary photography, including melanomagram, is considered investigational and not medically necessary in all cases.",
            "conditions": null
          },
          {
            "medical_act": "Evaluation of skin lesions",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The following technologies are considered investigational and not medically necessary for the evaluation of skin lesions:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Confocal scanning laser microscopy",
                  "conditions": null
                },
                {
                  "desc": "Electrical impedance spectroscopy",
                  "conditions": null
                },
                {
                  "desc": "Elastic scattering spectroscopy",
                  "conditions": null
                },
                {
                  "desc": "Molecular fluorescent imaging",
                  "conditions": null
                },
                {
                  "desc": "Multi-spectral image analysis",
                  "conditions": null
                },
                {
                  "desc": "Multiphoton laser scanning microscopy",
                  "conditions": null
                },
                {
                  "desc": "Optical coherence tomography",
                  "conditions": null
                },
                {
                  "desc": "Photoacoustic microscopy",
                  "conditions": null
                },
                {
                  "desc": "Quantitative infrared imaging",
                  "conditions": null
                },
                {
                  "desc": "Raman spectroscopy",
                  "conditions": null
                },
                {
                  "desc": "Ultrasonography",
                  "conditions": null
                },
                {
                  "desc": "Visual image analysis",
                  "conditions": null
                }
              ]
            }
          }
        ],
        "usage": {
          "total_tokens": 1600,
          "prompt_tokens": 1064,
          "completion_tokens": 536,
          "total_cost": 0.01336,
          "processing_time": 13.733202934265137
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050096.html",
    "subject": "Idiopathic Environmental Illness (IEI)",
    "document_number": "MED.00059",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Laboratory tests designed to affirm the diagnosis of idiopathic environmental illness are considered <strong>investigational and not medically necessary.</strong></p>\n<p>Treatment of idiopathic environmental illness with avoidance therapy, elimination diets, neutralizing therapy of chemical and food extracts, or medical therapy is considered <strong>investigational and not medically necessary.</strong></p>",
    "content": "Investigational and Not Medically Necessary:\nLaboratory tests designed to affirm the diagnosis of idiopathic environmental illness are considered investigational and not medically necessary.\nTreatment of idiopathic environmental illness with avoidance therapy, elimination diets, neutralizing therapy of chemical and food extracts, or medical therapy is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Laboratory tests designed to affirm the diagnosis of idiopathic environmental illness",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Laboratory tests designed to affirm the diagnosis of idiopathic environmental illness are considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Treatment of idiopathic environmental illness",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Treatment of idiopathic environmental illness with avoidance therapy, elimination diets, neutralizing therapy of chemical and food extracts, or medical therapy is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1046,
          "prompt_tokens": 877,
          "completion_tokens": 169,
          "total_cost": 0.00692,
          "processing_time": 2.976536989212036
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050108.html",
    "subject": "Optical Detection for Screening and Identification of Cervical Cancer",
    "document_number": "MED.00087",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of optical detection for the detection or identification of cervical cancer is considered <strong>investigational and not medically necessary.</strong></p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of optical detection for the detection or identification of cervical cancer is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Optical Detection for Cervical Cancer",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of optical detection for the detection or identification of cervical cancer is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 920,
          "prompt_tokens": 843,
          "completion_tokens": 77,
          "total_cost": 0.00537,
          "processing_time": 1.3395442962646484
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050051.html",
    "subject": "Non-Invasive Measurement of Left Ventricular End Diastolic Pressure in the Outpatient Setting",
    "document_number": "MED.00053",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Non-invasive measurement of left ventricular end diastolic pressure in the outpatient setting is considered <strong>investigational and not medically necessary</strong><strong>.</strong></p>",
    "content": "Investigational and Not Medically Necessary:\nNon-invasive measurement of left ventricular end diastolic pressure in the outpatient setting is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Non-invasive measurement of left ventricular end diastolic pressure in the outpatient setting",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Non-invasive measurement of left ventricular end diastolic pressure in the outpatient setting is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 932,
          "prompt_tokens": 845,
          "completion_tokens": 87,
          "total_cost": 0.005529999999999999,
          "processing_time": 2.10737681388855
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_d085098.html",
    "subject": "Biofeedback and Neurofeedback",
    "document_number": "MED.00125",
    "publish_date": "04/01/2024",
    "status": "Revised",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>Biofeedback therapy is considered <strong>medically necessary</strong> when the following criteria are met:</p>\n<li>Supervised by a physician or licensed practitioner; <strong>and</strong></li>\n<li>Used as treatment for at least one of the following conditions:\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t<li>Cancer pain; <strong>or</strong></li>\t\t<li>Chronic back pain as part of a rehabilitation program; <strong>or</strong></li>\t\t<li>Chronic constipation; <strong>or</strong></li>\t\t<li>Fecal incontinence; <strong>or</strong></li>\t\t<li>Levator ani syndrome, also known as anorectal pain syndrome; <strong>or</strong></li>\t\t<li>Migraine or tension headaches; <strong>or</strong></li>\t\t<li>Urinary incontinence.</li>\t</ol>\t</li>\n<li>Cancer pain; <strong>or</strong></li>\n<li>Chronic back pain as part of a rehabilitation program; <strong>or</strong></li>\n<li>Chronic constipation; <strong>or</strong></li>\n<li>Fecal incontinence; <strong>or</strong></li>\n<li>Levator ani syndrome, also known as anorectal pain syndrome; <strong>or</strong></li>\n<li>Migraine or tension headaches; <strong>or</strong></li>\n<li>Urinary incontinence.</li>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Biofeedback therapy is considered <strong>investigational and not medically necessary </strong>when the criteria above are not met, and<strong> </strong>for all other indications.</p>\n<p style=\"margin-right:14px\">Neurofeedback, also known as electroencephalogram (EEG) biofeedback, is considered <strong>investigational and not medically necessary</strong> for all indications including, but not limited to:</p>\n<li>asthma;</li>\n<li>attention-deficit hyperactivity disorder;</li>\n<li>autistic spectrum disorders;</li>\n<li>cardiovascular conditions;</li>\n<li>cluster headaches;</li>\n<li>epilepsy;</li>\n<li>post-traumatic stress disorder;</li>\n<li>substance use disorders;</li>\n<li>traumatic brain injury.</li>\n<p style=\"margin-right:4px\">The use of home biofeedback devices is considered <strong>investigational and not medically necessary </strong>for all indications.</p>",
    "content": "Medically Necessary:\nBiofeedback therapy is considered medically necessary when the following criteria are met:\n<li>Supervised by a physician or licensed practitioner; and</li>\n<li>Used as treatment for at least one of the following conditions:\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Cancer pain; or</li> <li>Chronic back pain as part of a rehabilitation program; or</li> <li>Chronic constipation; or</li> <li>Fecal incontinence; or</li> <li>Levator ani syndrome, also known as anorectal pain syndrome; or</li> <li>Migraine or tension headaches; or</li> <li>Urinary incontinence.</li> </ol> </li>\n<li>Cancer pain; or</li>\n<li>Chronic back pain as part of a rehabilitation program; or</li>\n<li>Chronic constipation; or</li>\n<li>Fecal incontinence; or</li>\n<li>Levator ani syndrome, also known as anorectal pain syndrome; or</li>\n<li>Migraine or tension headaches; or</li>\n<li>Urinary incontinence.</li>\nInvestigational and Not Medically Necessary:\nBiofeedback therapy is considered investigational and not medically necessary when the criteria above are not met, and for all other indications.\nNeurofeedback, also known as electroencephalogram (EEG) biofeedback, is considered investigational and not medically necessary for all indications including, but not limited to:\n<li>asthma;</li>\n<li>attention-deficit hyperactivity disorder;</li>\n<li>autistic spectrum disorders;</li>\n<li>cardiovascular conditions;</li>\n<li>cluster headaches;</li>\n<li>epilepsy;</li>\n<li>post-traumatic stress disorder;</li>\n<li>substance use disorders;</li>\n<li>traumatic brain injury.</li>\nThe use of home biofeedback devices is considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Biofeedback therapy",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Biofeedback therapy is considered medically necessary when the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Supervised by a physician or licensed practitioner",
                  "conditions": null
                },
                {
                  "ANY": [
                    {
                      "desc": "Cancer pain",
                      "conditions": null
                    },
                    {
                      "desc": "Chronic back pain as part of a rehabilitation program",
                      "conditions": null
                    },
                    {
                      "desc": "Chronic constipation",
                      "conditions": null
                    },
                    {
                      "desc": "Fecal incontinence",
                      "conditions": null
                    },
                    {
                      "desc": "Levator ani syndrome, also known as anorectal pain syndrome",
                      "conditions": null
                    },
                    {
                      "desc": "Migraine or tension headaches",
                      "conditions": null
                    },
                    {
                      "desc": "Urinary incontinence",
                      "conditions": null
                    }
                  ]
                }
              ]
            }
          },
          {
            "medical_act": "Biofeedback therapy",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Biofeedback therapy is considered investigational and not medically necessary when the criteria above are not met, and for all other indications.",
            "conditions": null
          },
          {
            "medical_act": "Neurofeedback (EEG biofeedback)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Neurofeedback, also known as electroencephalogram (EEG) biofeedback, is considered investigational and not medically necessary for all indications including, but not limited to:",
            "conditions": {
              "ANY": [
                {
                  "desc": "asthma",
                  "conditions": null
                },
                {
                  "desc": "attention-deficit hyperactivity disorder",
                  "conditions": null
                },
                {
                  "desc": "autistic spectrum disorders",
                  "conditions": null
                },
                {
                  "desc": "cardiovascular conditions",
                  "conditions": null
                },
                {
                  "desc": "cluster headaches",
                  "conditions": null
                },
                {
                  "desc": "epilepsy",
                  "conditions": null
                },
                {
                  "desc": "post-traumatic stress disorder",
                  "conditions": null
                },
                {
                  "desc": "substance use disorders",
                  "conditions": null
                },
                {
                  "desc": "traumatic brain injury",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Home biofeedback devices",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of home biofeedback devices is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1846,
          "prompt_tokens": 1233,
          "completion_tokens": 613,
          "total_cost": 0.01536,
          "processing_time": 11.308424234390259
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050505.html",
    "subject": "Wearable Cardioverter Defibrillators",
    "document_number": "MED.00055",
    "publish_date": "04/01/2024",
    "status": "Reviewed",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>The wearable cardioverter defibrillator is considered <strong>medically necessary</strong> for individuals at high-risk of sudden cardiac arrest, who meet the following criteria (A and B):</p>\n<li>Individuals must meet the medical necessity criteria for an implantable cardioverter defibrillator*; <strong>and</strong></li>\n<li>Individuals must have ONE of the following documented medical contraindications to implantation of an implantable cardioverter defibrillator (1, 2, or 3):\t<ol>\t\t<li>Those awaiting a heart transplantation - on waiting list and meet medical necessity criteria for heart transplantation;** <strong>or </strong></li>\t\t<li>Those with a previously implanted cardioverter defibrillator that requires explantation due to infection (for example, device pocket or lead infection, endocarditis) with waiting period before reimplantation of an implantable cardioverter defibrillator; <strong>or</strong></li>\t\t<li>Those with an infectious process or other temporary condition (for example, recovery from surgery, lack of vascular access) that precludes immediate implantation of an implantable cardioverter defibrillator.</li>\t</ol>\t</li>\n<li>Those awaiting a heart transplantation - on waiting list and meet medical necessity criteria for heart transplantation;** <strong>or </strong></li>\n<li>Those with a previously implanted cardioverter defibrillator that requires explantation due to infection (for example, device pocket or lead infection, endocarditis) with waiting period before reimplantation of an implantable cardioverter defibrillator; <strong>or</strong></li>\n<li>Those with an infectious process or other temporary condition (for example, recovery from surgery, lack of vascular access) that precludes immediate implantation of an implantable cardioverter defibrillator.</li>\n<p style=\"margin-left:22px\"><strong>&nbsp;*</strong> Refer to applicable implantable cardioverter defibrillator guidelines used by the plan<br><strong>**</strong>Refer to <em>TRANS.00033</em> <em>Heart Transplantation</em></p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The wearable cardioverter defibrillator is considered <strong>investigational and not medically necessary</strong> when the criteria listed above are not met.</p>",
    "content": "Medically Necessary:\nThe wearable cardioverter defibrillator is considered medically necessary for individuals at high-risk of sudden cardiac arrest, who meet the following criteria (A and B):\n<li>Individuals must meet the medical necessity criteria for an implantable cardioverter defibrillator*; and</li>\n<li>Individuals must have ONE of the following documented medical contraindications to implantation of an implantable cardioverter defibrillator (1, 2, or 3):\t<ol> <li>Those awaiting a heart transplantation - on waiting list and meet medical necessity criteria for heart transplantation;** or </li> <li>Those with a previously implanted cardioverter defibrillator that requires explantation due to infection (for example, device pocket or lead infection, endocarditis) with waiting period before reimplantation of an implantable cardioverter defibrillator; or</li> <li>Those with an infectious process or other temporary condition (for example, recovery from surgery, lack of vascular access) that precludes immediate implantation of an implantable cardioverter defibrillator.</li> </ol> </li>\n<li>Those awaiting a heart transplantation - on waiting list and meet medical necessity criteria for heart transplantation;** or </li>\n<li>Those with a previously implanted cardioverter defibrillator that requires explantation due to infection (for example, device pocket or lead infection, endocarditis) with waiting period before reimplantation of an implantable cardioverter defibrillator; or</li>\n<li>Those with an infectious process or other temporary condition (for example, recovery from surgery, lack of vascular access) that precludes immediate implantation of an implantable cardioverter defibrillator.</li>\n\u00a0* Refer to applicable implantable cardioverter defibrillator guidelines used by the plan<br/>**Refer to TRANS.00033 Heart Transplantation\nInvestigational and Not Medically Necessary:\nThe wearable cardioverter defibrillator is considered investigational and not medically necessary when the criteria listed above are not met.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Wearable Cardioverter Defibrillator",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "The wearable cardioverter defibrillator is considered medically necessary for individuals at high-risk of sudden cardiac arrest, who meet the following criteria (A and B):",
            "conditions": {
              "ALL": [
                {
                  "desc": "Individuals must meet the medical necessity criteria for an implantable cardioverter defibrillator*",
                  "conditions": null
                },
                {
                  "ANY": [
                    {
                      "desc": "Those awaiting a heart transplantation - on waiting list and meet medical necessity criteria for heart transplantation;**",
                      "conditions": null
                    },
                    {
                      "desc": "Those with a previously implanted cardioverter defibrillator that requires explantation due to infection (for example, device pocket or lead infection, endocarditis) with waiting period before reimplantation of an implantable cardioverter defibrillator",
                      "conditions": null
                    },
                    {
                      "desc": "Those with an infectious process or other temporary condition (for example, recovery from surgery, lack of vascular access) that precludes immediate implantation of an implantable cardioverter defibrillator",
                      "conditions": null
                    }
                  ]
                }
              ]
            }
          },
          {
            "medical_act": "Wearable Cardioverter Defibrillator",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The wearable cardioverter defibrillator is considered investigational and not medically necessary when the criteria listed above are not met.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1589,
          "prompt_tokens": 1224,
          "completion_tokens": 365,
          "total_cost": 0.011595000000000001,
          "processing_time": 6.462132930755615
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e001856.html",
    "subject": "Gene Therapy for Beta Thalassemia",
    "document_number": "MED.00140",
    "publish_date": "02/22/2024",
    "status": "Revised",
    "last_review_date": "02/15/2024",
    "html_content": "<p style=\"margin-bottom:8px\"><strong>Medically Necessary:</strong></p>\n<p>A one-time infusion of betibeglogene autotemcel is considered <strong>medically necessary</strong> in individuals when <strong>all</strong> of the following criteria are met:</p>\n<li>Diagnosis of beta thalassemia; <strong>and</strong></li>\n<li>Transfusion-dependent disease (that is, needing at least 8 transfusions or at least 100 ml per kilogram of body weight of packed red cells per year in the previous 2 years); <strong>and</strong></li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor*; <strong>and</strong></li>\n<li>Has no evidence of severe iron overload (for example, T2*-weighted magnetic resonance imaging [MRI] measurements of myocardial iron greater than 10 msec); <strong>and</strong></li>\n<li>No serious concomitant illness (for example, advanced liver disease, uncorrected bleeding disorder, current malignancy, myeloproliferative and/or immunodeficiency disorder, uncontrolled seizure disorder).</li>\n<p style=\"margin-left:40px\">*Documentation that a suitable donor has not been identified, for example, a matched related donor or matched (HLA 8/8 or 7/8) unrelated donor.</p>\n<p>A one-time infusion of exagamglogene autotemcel is considered <strong>medically necessary</strong> in individuals when <strong>all</strong> of the following criteria are met:</p>\n<li>Diagnosis of beta thalassemia; <strong>and</strong></li>\n<li>12 years of age or older; <strong>and</strong></li>\n<li>Transfusion-dependent disease (that is, needing at least 8 transfusions or at least 100 ml per kilogram of body weight of packed red cells per year in the previous 2 years); <strong>and</strong></li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor*; <strong>and</strong></li>\n<li>Has no evidence of severe iron overload (for example, T2*-weighted magnetic resonance imaging [MRI] measurements of myocardial iron greater than 10 msec); <strong>and</strong></li>\n<li>No serious concomitant illness (for example, advanced liver disease, uncorrected bleeding disorder, current malignancy, myeloproliferative and/or immunodeficiency disorder, uncontrolled seizure disorder).</li>\n<p style=\"margin-left:40px\">*Documentation that a suitable donor has not been identified, for example, a matched related donor or matched (HLA 8/8 or 7/8) unrelated donor.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Gene therapy for beta thalassemia is considered <strong>investigational and not medically necessary</strong> when the criteria above are not met.</p>",
    "content": "Medically Necessary:\nA one-time infusion of betibeglogene autotemcel is considered medically necessary in individuals when all of the following criteria are met:\n<li>Diagnosis of beta thalassemia; and</li>\n<li>Transfusion-dependent disease (that is, needing at least 8 transfusions or at least 100 ml per kilogram of body weight of packed red cells per year in the previous 2 years); and</li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor*; and</li>\n<li>Has no evidence of severe iron overload (for example, T2*-weighted magnetic resonance imaging [MRI] measurements of myocardial iron greater than 10 msec); and</li>\n<li>No serious concomitant illness (for example, advanced liver disease, uncorrected bleeding disorder, current malignancy, myeloproliferative and/or immunodeficiency disorder, uncontrolled seizure disorder).</li>\n*Documentation that a suitable donor has not been identified, for example, a matched related donor or matched (HLA 8/8 or 7/8) unrelated donor.\nA one-time infusion of exagamglogene autotemcel is considered medically necessary in individuals when all of the following criteria are met:\n<li>Diagnosis of beta thalassemia; and</li>\n<li>12 years of age or older; and</li>\n<li>Transfusion-dependent disease (that is, needing at least 8 transfusions or at least 100 ml per kilogram of body weight of packed red cells per year in the previous 2 years); and</li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor*; and</li>\n<li>Has no evidence of severe iron overload (for example, T2*-weighted magnetic resonance imaging [MRI] measurements of myocardial iron greater than 10 msec); and</li>\n<li>No serious concomitant illness (for example, advanced liver disease, uncorrected bleeding disorder, current malignancy, myeloproliferative and/or immunodeficiency disorder, uncontrolled seizure disorder).</li>\n*Documentation that a suitable donor has not been identified, for example, a matched related donor or matched (HLA 8/8 or 7/8) unrelated donor.\nInvestigational and Not Medically Necessary:\nGene therapy for beta thalassemia is considered investigational and not medically necessary when the criteria above are not met.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "One-time infusion of betibeglogene autotemcel",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A one-time infusion of betibeglogene autotemcel is considered medically necessary in individuals when all of the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Diagnosis of beta thalassemia",
                  "conditions": null
                },
                {
                  "desc": "Transfusion-dependent disease (that is, needing at least 8 transfusions or at least 100 ml per kilogram of body weight of packed red cells per year in the previous 2 years)",
                  "conditions": null
                },
                {
                  "desc": "The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor",
                  "conditions": null
                },
                {
                  "desc": "Has no evidence of severe iron overload (for example, T2*-weighted magnetic resonance imaging [MRI] measurements of myocardial iron greater than 10 msec)",
                  "conditions": null
                },
                {
                  "desc": "No serious concomitant illness (for example, advanced liver disease, uncorrected bleeding disorder, current malignancy, myeloproliferative and/or immunodeficiency disorder, uncontrolled seizure disorder)",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "One-time infusion of exagamglogene autotemcel",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A one-time infusion of exagamglogene autotemcel is considered medically necessary in individuals when all of the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Diagnosis of beta thalassemia",
                  "conditions": null
                },
                {
                  "desc": "12 years of age or older",
                  "conditions": null
                },
                {
                  "desc": "Transfusion-dependent disease (that is, needing at least 8 transfusions or at least 100 ml per kilogram of body weight of packed red cells per year in the previous 2 years)",
                  "conditions": null
                },
                {
                  "desc": "The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor",
                  "conditions": null
                },
                {
                  "desc": "Has no evidence of severe iron overload (for example, T2*-weighted magnetic resonance imaging [MRI] measurements of myocardial iron greater than 10 msec)",
                  "conditions": null
                },
                {
                  "desc": "No serious concomitant illness (for example, advanced liver disease, uncorrected bleeding disorder, current malignancy, myeloproliferative and/or immunodeficiency disorder, uncontrolled seizure disorder)",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Gene therapy for beta thalassemia",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Gene therapy for beta thalassemia is considered investigational and not medically necessary when the criteria above are not met.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 2020,
          "prompt_tokens": 1336,
          "completion_tokens": 684,
          "total_cost": 0.01694,
          "processing_time": 10.964905977249146
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e002738.html",
    "subject": "Gene Therapy for Sickle Cell Disease",
    "document_number": "MED.00146",
    "publish_date": "01/18/2024",
    "status": "New",
    "last_review_date": "01/16/2024",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>A one-time infusion of exagamglogene autotemcel is considered <strong>medically necessary</strong> in individuals when <strong>all</strong> of the following criteria are met:</p>\n<li>Diagnosis of sickle cell disease; <strong>and</strong></li>\n<li>At least 4 severe vaso-occlusive crises in the previous 2 years; <strong>and</strong></li>\n<li>12 years of age and older; <strong>and</strong></li>\n<li>Hydroxyurea therapy failure or intolerance; <strong>and</strong></li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor*; <strong>and</strong></li>\n<li>No serious concomitant illness (for example, advanced liver disease, clinically significant active infection, severe cerebral vasculopathy, clinically significant pulmonary hypertension, inadequate pulmonary or cardiac function, prior or current malignancy other than previously treated non-life-threatening tumors, immunodeficiency disorder); <strong>and</strong></li>\n<li>No prior receipt of gene therapy.</li>\n<p>A one-time infusion of lovotibeglogene autotemcel is considered <strong>medically necessary</strong> in individuals when <strong>all</strong> of the following criteria are met:</p>\n<li>Diagnosis of sickle cell disease; <strong>and</strong></li>\n<li>At least 4 severe vaso-occlusive crises in the previous 2 years; <strong>and</strong></li>\n<li>12 years of age and older; <strong>and</strong></li>\n<li>Hydroxyurea therapy failure or intolerance; <strong>and</strong></li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor*; <strong>and</strong></li>\n<li>No serious concomitant illness (for example, advanced liver disease, clinically significant active infection, severe cerebral vasculopathy, clinically significant pulmonary hypertension, inadequate pulmonary or cardiac function, prior or current malignancy other than previously treated non-life-threatening tumors, immunodeficiency disorder)<strong> and</strong></li>\n<li>No prior receipt of gene therapy.</li>\n<p style=\"margin-left:40px\">*Documentation that a suitable donor has not been identified, for example, a matched related donor or matched (HLA 8/8 or 7/8) unrelated donor.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Gene therapy for sickle cell disease is considered <strong>investigational and not medically necessary</strong> when the criteria above are not met.</p>",
    "content": "Medically Necessary:\nA one-time infusion of exagamglogene autotemcel is considered medically necessary in individuals when all of the following criteria are met:\n<li>Diagnosis of sickle cell disease; and</li>\n<li>At least 4 severe vaso-occlusive crises in the previous 2 years; and</li>\n<li>12 years of age and older; and</li>\n<li>Hydroxyurea therapy failure or intolerance; and</li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor*; and</li>\n<li>No serious concomitant illness (for example, advanced liver disease, clinically significant active infection, severe cerebral vasculopathy, clinically significant pulmonary hypertension, inadequate pulmonary or cardiac function, prior or current malignancy other than previously treated non-life-threatening tumors, immunodeficiency disorder); and</li>\n<li>No prior receipt of gene therapy.</li>\nA one-time infusion of lovotibeglogene autotemcel is considered medically necessary in individuals when all of the following criteria are met:\n<li>Diagnosis of sickle cell disease; and</li>\n<li>At least 4 severe vaso-occlusive crises in the previous 2 years; and</li>\n<li>12 years of age and older; and</li>\n<li>Hydroxyurea therapy failure or intolerance; and</li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor*; and</li>\n<li>No serious concomitant illness (for example, advanced liver disease, clinically significant active infection, severe cerebral vasculopathy, clinically significant pulmonary hypertension, inadequate pulmonary or cardiac function, prior or current malignancy other than previously treated non-life-threatening tumors, immunodeficiency disorder) and</li>\n<li>No prior receipt of gene therapy.</li>\n*Documentation that a suitable donor has not been identified, for example, a matched related donor or matched (HLA 8/8 or 7/8) unrelated donor.\nInvestigational and Not Medically Necessary:\nGene therapy for sickle cell disease is considered investigational and not medically necessary when the criteria above are not met.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "One-time infusion of exagamglogene autotemcel",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A one-time infusion of exagamglogene autotemcel is considered medically necessary in individuals when all of the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Diagnosis of sickle cell disease",
                  "conditions": null
                },
                {
                  "desc": "At least 4 severe vaso-occlusive crises in the previous 2 years",
                  "conditions": null
                },
                {
                  "desc": "12 years of age and older",
                  "conditions": null
                },
                {
                  "desc": "Hydroxyurea therapy failure or intolerance",
                  "conditions": null
                },
                {
                  "desc": "The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor",
                  "conditions": null
                },
                {
                  "desc": "No serious concomitant illness (for example, advanced liver disease, clinically significant active infection, severe cerebral vasculopathy, clinically significant pulmonary hypertension, inadequate pulmonary or cardiac function, prior or current malignancy other than previously treated non-life-threatening tumors, immunodeficiency disorder)",
                  "conditions": null
                },
                {
                  "desc": "No prior receipt of gene therapy",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "One-time infusion of lovotibeglogene autotemcel",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A one-time infusion of lovotibeglogene autotemcel is considered medically necessary in individuals when all of the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Diagnosis of sickle cell disease",
                  "conditions": null
                },
                {
                  "desc": "At least 4 severe vaso-occlusive crises in the previous 2 years",
                  "conditions": null
                },
                {
                  "desc": "12 years of age and older",
                  "conditions": null
                },
                {
                  "desc": "Hydroxyurea therapy failure or intolerance",
                  "conditions": null
                },
                {
                  "desc": "The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor",
                  "conditions": null
                },
                {
                  "desc": "No serious concomitant illness (for example, advanced liver disease, clinically significant active infection, severe cerebral vasculopathy, clinically significant pulmonary hypertension, inadequate pulmonary or cardiac function, prior or current malignancy other than previously treated non-life-threatening tumors, immunodeficiency disorder)",
                  "conditions": null
                },
                {
                  "desc": "No prior receipt of gene therapy",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Gene therapy for sickle cell disease",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Gene therapy for sickle cell disease is considered investigational and not medically necessary when the criteria above are not met.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1951,
          "prompt_tokens": 1275,
          "completion_tokens": 676,
          "total_cost": 0.016515,
          "processing_time": 12.28743600845337
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e001905.html",
    "subject": "Gene Therapy for Cerebral Adrenoleukodystrophy",
    "document_number": "MED.00142",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>A one-time infusion of elivaldogene autotemcel is considered <strong>medically necessary</strong> when <strong>all</strong> of the following criteria are met:</p>\n<li>The individual is in the early stages of cerebral adrenoleukodystrophy (CALD), as confirmed by the following:\t<ol>\t\t<li>Elevated very long chain fatty acid levels; <strong>and</strong></li>\t\t<li>Confirmation of the presence of an <em>ABCD1 </em>genetic mutation; <strong>and</strong></li>\t\t<li>CALD-specific Neurological Function Scale (NFS) score of 0 or 1; <strong>and</strong></li>\t\t<li>Active central nervous system (CNS) disease with demyelinating lesions demonstrated on brain gadolinium-enhanced MRI with Loes score between 0.5 and 9.0 on the 34-point scale; <strong>and</strong></li>\t</ol>\t</li>\n<li>Elevated very long chain fatty acid levels; <strong>and</strong></li>\n<li>Confirmation of the presence of an <em>ABCD1 </em>genetic mutation; <strong>and</strong></li>\n<li>CALD-specific Neurological Function Scale (NFS) score of 0 or 1; <strong>and</strong></li>\n<li>Active central nervous system (CNS) disease with demyelinating lesions demonstrated on brain gadolinium-enhanced MRI with Loes score between 0.5 and 9.0 on the 34-point scale; <strong>and</strong></li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor*; <strong>and</strong></li>\n<li>The individual is 4 to 17 years of age; <strong>and</strong></li>\n<li>Absence of any clinically significant cardiovascular, hepatic, hematological, renal or pulmonary disease, or other disease or condition that poses a contraindication to the procedure, including myeloablative conditioning.</li>\n<p>* Documentation that a suitable donor has not been identified, for example, a matched related donor or matched (HLA 8/8 or 7/8) unrelated donor.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Elivaldogene autotemcel is considered <strong>investigational and not medically necessary</strong> when the criteria above are not met, including for repeat infusions.</p>",
    "content": "Medically Necessary:\nA one-time infusion of elivaldogene autotemcel is considered medically necessary when all of the following criteria are met:\n<li>The individual is in the early stages of cerebral adrenoleukodystrophy (CALD), as confirmed by the following:\t<ol> <li>Elevated very long chain fatty acid levels; and</li> <li>Confirmation of the presence of an ABCD1 genetic mutation; and</li> <li>CALD-specific Neurological Function Scale (NFS) score of 0 or 1; and</li> <li>Active central nervous system (CNS) disease with demyelinating lesions demonstrated on brain gadolinium-enhanced MRI with Loes score between 0.5 and 9.0 on the 34-point scale; and</li> </ol> </li>\n<li>Elevated very long chain fatty acid levels; and</li>\n<li>Confirmation of the presence of an ABCD1 genetic mutation; and</li>\n<li>CALD-specific Neurological Function Scale (NFS) score of 0 or 1; and</li>\n<li>Active central nervous system (CNS) disease with demyelinating lesions demonstrated on brain gadolinium-enhanced MRI with Loes score between 0.5 and 9.0 on the 34-point scale; and</li>\n<li>The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor*; and</li>\n<li>The individual is 4 to 17 years of age; and</li>\n<li>Absence of any clinically significant cardiovascular, hepatic, hematological, renal or pulmonary disease, or other disease or condition that poses a contraindication to the procedure, including myeloablative conditioning.</li>\n* Documentation that a suitable donor has not been identified, for example, a matched related donor or matched (HLA 8/8 or 7/8) unrelated donor.\nInvestigational and Not Medically Necessary:\nElivaldogene autotemcel is considered investigational and not medically necessary when the criteria above are not met, including for repeat infusions.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Elivaldogene autotemcel infusion",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A one-time infusion of elivaldogene autotemcel is considered medically necessary when all of the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "The individual is in the early stages of cerebral adrenoleukodystrophy (CALD), as confirmed by the following:",
                  "conditions": {
                    "ALL": [
                      {
                        "desc": "Elevated very long chain fatty acid levels",
                        "conditions": null
                      },
                      {
                        "desc": "Confirmation of the presence of an ABCD1 genetic mutation",
                        "conditions": null
                      },
                      {
                        "desc": "CALD-specific Neurological Function Scale (NFS) score of 0 or 1",
                        "conditions": null
                      },
                      {
                        "desc": "Active central nervous system (CNS) disease with demyelinating lesions demonstrated on brain gadolinium-enhanced MRI with Loes score between 0.5 and 9.0 on the 34-point scale",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Elevated very long chain fatty acid levels",
                  "conditions": null
                },
                {
                  "desc": "Confirmation of the presence of an ABCD1 genetic mutation",
                  "conditions": null
                },
                {
                  "desc": "CALD-specific Neurological Function Scale (NFS) score of 0 or 1",
                  "conditions": null
                },
                {
                  "desc": "Active central nervous system (CNS) disease with demyelinating lesions demonstrated on brain gadolinium-enhanced MRI with Loes score between 0.5 and 9.0 on the 34-point scale",
                  "conditions": null
                },
                {
                  "desc": "The individual is a candidate for an allogeneic hematopoietic cell transplantation, but ineligible due the absence of a donor",
                  "conditions": null
                },
                {
                  "desc": "The individual is 4 to 17 years of age",
                  "conditions": null
                },
                {
                  "desc": "Absence of any clinically significant cardiovascular, hepatic, hematological, renal or pulmonary disease, or other disease or condition that poses a contraindication to the procedure, including myeloablative conditioning",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Elivaldogene autotemcel infusion",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Elivaldogene autotemcel is considered investigational and not medically necessary when the criteria above are not met, including for repeat infusions.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1849,
          "prompt_tokens": 1265,
          "completion_tokens": 584,
          "total_cost": 0.015084999999999998,
          "processing_time": 8.775679111480713
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e002058.html",
    "subject": "Ingestible Devices for the Treatment of Constipation",
    "document_number": "MED.00143",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Ingestible devices for the treatment of constipation are considered <strong>investigational and not medically necessary</strong>.</p>",
    "content": "Investigational and Not Medically Necessary:\nIngestible devices for the treatment of constipation are considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Ingestible devices for the treatment of constipation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Ingestible devices for the treatment of constipation are considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 914,
          "prompt_tokens": 839,
          "completion_tokens": 75,
          "total_cost": 0.00532,
          "processing_time": 1.4396159648895264
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e000516.html",
    "subject": "Electronic Home Visual Field Monitoring",
    "document_number": "MED.00131",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of electronic home visual field monitoring is considered <strong>investigational and not medically necessary</strong> for all indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of electronic home visual field monitoring is considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Electronic Home Visual Field Monitoring",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of electronic home visual field monitoring is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 914,
          "prompt_tokens": 841,
          "completion_tokens": 73,
          "total_cost": 0.005299999999999999,
          "processing_time": 1.362455129623413
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c150985.html",
    "subject": "Silver-based Products for Wound and Soft Tissue Applications",
    "document_number": "MED.00110",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Antimicrobial silver wound dressings, (for example, Acticoat, Actisorb, and Silversorb) are considered <strong>investigational and not medically necessary </strong>for all applications.</p>",
    "content": "Investigational and Not Medically Necessary:\nAntimicrobial silver wound dressings, (for example, Acticoat, Actisorb, and Silversorb) are considered investigational and not medically necessary for all applications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Antimicrobial silver wound dressings",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Antimicrobial silver wound dressings, (for example, Acticoat, Actisorb, and Silversorb) are considered investigational and not medically necessary for all applications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 950,
          "prompt_tokens": 858,
          "completion_tokens": 92,
          "total_cost": 0.0056700000000000006,
          "processing_time": 2.149749994277954
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050300.html",
    "subject": "Insulin Potentiation Therapy",
    "document_number": "MED.00128",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Insulin potentiation therapy (IPT) is considered <strong>investigational and not medically necessary</strong> for the treatment of cancer, infectious diseases, chronic degenerative disorders, and all other conditions.</p>",
    "content": "Investigational and Not Medically Necessary:\nInsulin potentiation therapy (IPT) is considered investigational and not medically necessary for the treatment of cancer, infectious diseases, chronic degenerative disorders, and all other conditions.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Insulin potentiation therapy (IPT)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Insulin potentiation therapy (IPT) is considered investigational and not medically necessary for the treatment of cancer, infectious diseases, chronic degenerative disorders, and all other conditions.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 949,
          "prompt_tokens": 857,
          "completion_tokens": 92,
          "total_cost": 0.005665,
          "processing_time": 1.8228790760040283
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_b083412.html",
    "subject": "Neural Therapy",
    "document_number": "MED.00097",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Neural therapy is considered <strong>investigational and not medically necessary </strong>for all indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nNeural therapy is considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Neural therapy",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Neural therapy is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 902,
          "prompt_tokens": 836,
          "completion_tokens": 66,
          "total_cost": 0.005169999999999999,
          "processing_time": 1.273792028427124
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050140.html",
    "subject": "Selected Sleep Testing Services",
    "document_number": "MED.00002",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>\u201cNap\u201d studies are considered <strong>investigational and not medically necessary </strong>either for screening purposes or as an alternative to polysomnography for the diagnosis of obstructive sleep apnea or narcolepsy.</p>\n<p>The following diagnostic tests are considered <strong>investigational and not medically necessary:</strong></p>\n<li>Diagnostic audio recording, with or without pulse oximetry, to document sleep apnea;</li>\n<li>Topographic brain mapping;</li>\n<li>Acoustic pharyngometry (Eccovision<sup>\u2122</sup> Acoustic Pharyngometer<sup>\u00ae</sup>);</li>\n<li>Actigraphy or static charge sensitive beds.</li>",
    "content": "Investigational and Not Medically Necessary:\n\u201cNap\u201d studies are considered investigational and not medically necessary either for screening purposes or as an alternative to polysomnography for the diagnosis of obstructive sleep apnea or narcolepsy.\nThe following diagnostic tests are considered investigational and not medically necessary:\n<li>Diagnostic audio recording, with or without pulse oximetry, to document sleep apnea;</li>\n<li>Topographic brain mapping;</li>\n<li>Acoustic pharyngometry (Eccovision<sup>\u2122</sup> Acoustic Pharyngometer<sup>\u00ae</sup>);</li>\n<li>Actigraphy or static charge sensitive beds.</li>",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Nap studies",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "\u201cNap\u201d studies are considered investigational and not medically necessary either for screening purposes or as an alternative to polysomnography for the diagnosis of obstructive sleep apnea or narcolepsy.",
            "conditions": null
          },
          {
            "medical_act": "Diagnostic tests",
            "sub_medical_act": "Diagnostic audio recording",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Diagnostic audio recording, with or without pulse oximetry, to document sleep apnea.",
            "conditions": null
          },
          {
            "medical_act": "Diagnostic tests",
            "sub_medical_act": "Topographic brain mapping",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Topographic brain mapping.",
            "conditions": null
          },
          {
            "medical_act": "Diagnostic tests",
            "sub_medical_act": "Acoustic pharyngometry",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Acoustic pharyngometry (Eccovision\u2122 Acoustic Pharyngometer\u00ae).",
            "conditions": null
          },
          {
            "medical_act": "Diagnostic tests",
            "sub_medical_act": "Actigraphy or static charge sensitive beds",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Actigraphy or static charge sensitive beds.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1293,
          "prompt_tokens": 947,
          "completion_tokens": 346,
          "total_cost": 0.009925,
          "processing_time": 6.2121100425720215
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050528.html",
    "subject": "Rhinophototherapy",
    "document_number": "MED.00091",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of rhinophototherapy is considered <strong>investigational and not medically necessary</strong> for all conditions, including but not limited to the treatment of allergic rhinitis and other nasal or sinus conditions.</p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of rhinophototherapy is considered investigational and not medically necessary for all conditions, including but not limited to the treatment of allergic rhinitis and other nasal or sinus conditions.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Rhinophototherapy",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of rhinophototherapy is considered investigational and not medically necessary for all conditions, including but not limited to the treatment of allergic rhinitis and other nasal or sinus conditions.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 948,
          "prompt_tokens": 858,
          "completion_tokens": 90,
          "total_cost": 0.00564,
          "processing_time": 1.9553747177124023
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050529.html",
    "subject": "Automated Nerve Conduction Testing",
    "document_number": "MED.00092",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Electrodiagnostic testing with automated, noninvasive nerve conduction testing devices is considered <strong>investigational</strong> <strong>and</strong> <strong>not medically necessary</strong> for all indications, including as an alternative method of performing nerve conduction velocity studies.</p>",
    "content": "Investigational and Not Medically Necessary:\nElectrodiagnostic testing with automated, noninvasive nerve conduction testing devices is considered investigational and not medically necessary for all indications, including as an alternative method of performing nerve conduction velocity studies.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Electrodiagnostic testing with automated, noninvasive nerve conduction testing devices",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Electrodiagnostic testing with automated, noninvasive nerve conduction testing devices is considered investigational and not medically necessary for all indications, including as an alternative method of performing nerve conduction velocity studies.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 962,
          "prompt_tokens": 860,
          "completion_tokens": 102,
          "total_cost": 0.00583,
          "processing_time": 2.2596840858459473
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c178379.html",
    "subject": "Outpatient Cardiac Hemodynamic Monitoring Using a Wireless Sensor for Heart Failure Management",
    "document_number": "MED.00115",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The implantation of a pressure sensor into the pulmonary artery for the purpose of wireless ambulatory monitoring of heart failure and all other indications is considered <strong>investigational and not medically necessary.</strong></p>",
    "content": "Investigational and Not Medically Necessary:\nThe implantation of a pressure sensor into the pulmonary artery for the purpose of wireless ambulatory monitoring of heart failure and all other indications is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Implantation of a pressure sensor into the pulmonary artery for the purpose of wireless ambulatory monitoring of heart failure and all other indications",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The implantation of a pressure sensor into the pulmonary artery for the purpose of wireless ambulatory monitoring of heart failure and all other indications is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 963,
          "prompt_tokens": 855,
          "completion_tokens": 108,
          "total_cost": 0.005895,
          "processing_time": 3.6546201705932617
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c178380.html",
    "subject": "Near-Infrared Spectroscopy Scanning for Brain Hematoma Screening",
    "document_number": "MED.00116",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Near-infrared spectroscopy scanning for brain hematoma screening (that is, InfraScanner) is considered <strong>investigational and not medically necessary</strong> for all indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nNear-infrared spectroscopy scanning for brain hematoma screening (that is, InfraScanner) is considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Near-infrared spectroscopy scanning for brain hematoma screening (that is, InfraScanner)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Near-infrared spectroscopy scanning for brain hematoma screening (that is, InfraScanner) is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 946,
          "prompt_tokens": 851,
          "completion_tokens": 95,
          "total_cost": 0.00568,
          "processing_time": 2.141946792602539
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050053.html",
    "subject": "MRI Guided High Intensity Focused Ultrasound Ablation for Non-Oncologic Indications",
    "document_number": "MED.00057",
    "publish_date": "01/03/2024",
    "status": "Revised",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Medically Necessary </strong></p>\n<li>Unilateral focused ultrasound thalamotomy is considered<strong> medically necessary </strong>for the treatment of adults with essential tremors when <strong>all</strong> of the following criteria are met:\t<ol start=\"1\" style=\"list-style-type:upper-alpha\">\t\t<li>Moderate to severe tremor of the hand (as defined by a score of 2 or greater on the clinical rating scale for tremor [CRST]); <strong>and</strong></li>\t\t<li>Failure of 2 or more tremor suppressant medications, as evidenced by persistent moderate to severe tremors, intolerable side effects of drug therapy or contraindications; <strong>and</strong></li>\t\t<li>At least 1 of the medications failed was a first line agent (propranolol or primidone).</li>\t</ol>\t</li>\n<li>Moderate to severe tremor of the hand (as defined by a score of 2 or greater on the clinical rating scale for tremor [CRST]); <strong>and</strong></li>\n<li>Failure of 2 or more tremor suppressant medications, as evidenced by persistent moderate to severe tremors, intolerable side effects of drug therapy or contraindications; <strong>and</strong></li>\n<li>At least 1 of the medications failed was a first line agent (propranolol or primidone).</li>\n<li>Unilateral focused ultrasound pallidotomy is considered <strong>medically necessary</strong> for the treatment of idiopathic Parkinson\u2019s disease in individuals who meet <strong>all</strong> of the following criteria:\t<ol start=\"1\" style=\"list-style-type:upper-alpha\">\t\t<li>Age 30 or older;<strong> and</strong></li>\t\t<li>Unilateral pallidotomy is used as an adjunct to medication treatment of idiopathic Parkinson\u2019s disease; <strong>and</strong></li>\t\t<li>Levodopa responsive (as defined by a 30% or greater reduction in the Movement Disorder Society- Unified Parkinson's Disease Rating Scale [MDS-UPDRS] motor subscale in the <em>on </em>versus <em>off</em> levodopa medication state; <strong>and</strong></li>\t\t<li>Moderate-to-severe motor complications as defined by at least <strong>one</strong> of the following:\t\t<ol>\t\t\t<li>MDS-UPDRS score of 20 or greater in the meds <em>off</em> condition; <strong>or</strong></li>\t\t\t<li>Motor complications on optimum medical treatment documented by at least <strong>one</strong> of the following:\t\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t\t<li>Dyskinesia (as defined by MDS-UPDRS item 4.2 score of 2 or greater in the meds <em>on</em> condition); <strong>or</strong></li>\t\t\t\t<li>Motor fluctuations (as defined by MDS-UPDRS item 4.4 score of 2 or greater);<br>\t\t\t\t<strong>and </strong></li>\t\t\t</ol>\t\t\t</li>\t\t</ol>\t\t</li>\t\t<li>The individual is <strong>not</strong> a candidate for <em>either</em> the following procedures:\t\t<ol>\t\t\t<li>Deep brain stimulation (DBS); <strong>or</strong></li>\t\t\t<li>Radiofrequency (RF) thermoablation;<br>\t\t\t<strong>and</strong></li>\t\t</ol>\t\t</li>\t\t<li>The absence of <strong>all </strong>of the following conditions:\t\t<ol>\t\t\t<li>Central neurodegenerative disease other than Parkinson\u2019s Disease (includes multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer\u2019s disease); <strong>or</strong></li>\t\t\t<li>Previous deep brain stimulation; <strong>or</strong></li>\t\t\t<li>Previous basal ganglia ablation procedure; <strong>or</strong></li>\t\t\t<li>Coagulopathy or current anticoagulant use which cannot be reversed; <strong>or</strong></li>\t\t\t<li>Intracranial tumor with significant anatomic distortion.</li>\t\t</ol>\t\t</li>\t</ol>\t</li>\n<li>Age 30 or older;<strong> and</strong></li>\n<li>Unilateral pallidotomy is used as an adjunct to medication treatment of idiopathic Parkinson\u2019s disease; <strong>and</strong></li>\n<li>Levodopa responsive (as defined by a 30% or greater reduction in the Movement Disorder Society- Unified Parkinson's Disease Rating Scale [MDS-UPDRS] motor subscale in the <em>on </em>versus <em>off</em> levodopa medication state; <strong>and</strong></li>\n<li>Moderate-to-severe motor complications as defined by at least <strong>one</strong> of the following:\t\t<ol>\t\t\t<li>MDS-UPDRS score of 20 or greater in the meds <em>off</em> condition; <strong>or</strong></li>\t\t\t<li>Motor complications on optimum medical treatment documented by at least <strong>one</strong> of the following:\t\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t\t<li>Dyskinesia (as defined by MDS-UPDRS item 4.2 score of 2 or greater in the meds <em>on</em> condition); <strong>or</strong></li>\t\t\t\t<li>Motor fluctuations (as defined by MDS-UPDRS item 4.4 score of 2 or greater);<br>\t\t\t\t<strong>and </strong></li>\t\t\t</ol>\t\t\t</li>\t\t</ol>\t\t</li>\n<li>MDS-UPDRS score of 20 or greater in the meds <em>off</em> condition; <strong>or</strong></li>\n<li>Motor complications on optimum medical treatment documented by at least <strong>one</strong> of the following:\t\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t\t<li>Dyskinesia (as defined by MDS-UPDRS item 4.2 score of 2 or greater in the meds <em>on</em> condition); <strong>or</strong></li>\t\t\t\t<li>Motor fluctuations (as defined by MDS-UPDRS item 4.4 score of 2 or greater);<br>\t\t\t\t<strong>and </strong></li>\t\t\t</ol>\t\t\t</li>\n<li>Dyskinesia (as defined by MDS-UPDRS item 4.2 score of 2 or greater in the meds <em>on</em> condition); <strong>or</strong></li>\n<li>Motor fluctuations (as defined by MDS-UPDRS item 4.4 score of 2 or greater);<br>\t\t\t\t<strong>and </strong></li>\n<li>The individual is <strong>not</strong> a candidate for <em>either</em> the following procedures:\t\t<ol>\t\t\t<li>Deep brain stimulation (DBS); <strong>or</strong></li>\t\t\t<li>Radiofrequency (RF) thermoablation;<br>\t\t\t<strong>and</strong></li>\t\t</ol>\t\t</li>\n<li>Deep brain stimulation (DBS); <strong>or</strong></li>\n<li>Radiofrequency (RF) thermoablation;<br>\t\t\t<strong>and</strong></li>\n<li>The absence of <strong>all </strong>of the following conditions:\t\t<ol>\t\t\t<li>Central neurodegenerative disease other than Parkinson\u2019s Disease (includes multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer\u2019s disease); <strong>or</strong></li>\t\t\t<li>Previous deep brain stimulation; <strong>or</strong></li>\t\t\t<li>Previous basal ganglia ablation procedure; <strong>or</strong></li>\t\t\t<li>Coagulopathy or current anticoagulant use which cannot be reversed; <strong>or</strong></li>\t\t\t<li>Intracranial tumor with significant anatomic distortion.</li>\t\t</ol>\t\t</li>\n<li>Central neurodegenerative disease other than Parkinson\u2019s Disease (includes multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer\u2019s disease); <strong>or</strong></li>\n<li>Previous deep brain stimulation; <strong>or</strong></li>\n<li>Previous basal ganglia ablation procedure; <strong>or</strong></li>\n<li>Coagulopathy or current anticoagulant use which cannot be reversed; <strong>or</strong></li>\n<li>Intracranial tumor with significant anatomic distortion.</li>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>MRI guided high intensity focused ultrasound ablation is considered <strong>investigational and not medically necessary</strong> when the criteria above are not met and for all other non-oncologic indications.</p>",
    "content": "Medically Necessary \n<li>Unilateral focused ultrasound thalamotomy is considered medically necessary for the treatment of adults with essential tremors when all of the following criteria are met:\t<ol start=\"1\" style=\"list-style-type:upper-alpha\"> <li>Moderate to severe tremor of the hand (as defined by a score of 2 or greater on the clinical rating scale for tremor [CRST]); and</li> <li>Failure of 2 or more tremor suppressant medications, as evidenced by persistent moderate to severe tremors, intolerable side effects of drug therapy or contraindications; and</li> <li>At least 1 of the medications failed was a first line agent (propranolol or primidone).</li> </ol> </li>\n<li>Moderate to severe tremor of the hand (as defined by a score of 2 or greater on the clinical rating scale for tremor [CRST]); and</li>\n<li>Failure of 2 or more tremor suppressant medications, as evidenced by persistent moderate to severe tremors, intolerable side effects of drug therapy or contraindications; and</li>\n<li>At least 1 of the medications failed was a first line agent (propranolol or primidone).</li>\n<li>Unilateral focused ultrasound pallidotomy is considered medically necessary for the treatment of idiopathic Parkinson\u2019s disease in individuals who meet all of the following criteria:\t<ol start=\"1\" style=\"list-style-type:upper-alpha\"> <li>Age 30 or older; and</li> <li>Unilateral pallidotomy is used as an adjunct to medication treatment of idiopathic Parkinson\u2019s disease; and</li> <li>Levodopa responsive (as defined by a 30% or greater reduction in the Movement Disorder Society- Unified Parkinson's Disease Rating Scale [MDS-UPDRS] motor subscale in the on versus off levodopa medication state; and</li> <li>Moderate-to-severe motor complications as defined by at least one of the following:\t\t<ol> <li>MDS-UPDRS score of 20 or greater in the meds off condition; or</li> <li>Motor complications on optimum medical treatment documented by at least one of the following:\t\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Dyskinesia (as defined by MDS-UPDRS item 4.2 score of 2 or greater in the meds on condition); or</li> <li>Motor fluctuations (as defined by MDS-UPDRS item 4.4 score of 2 or greater);<br/> and </li> </ol> </li> </ol> </li> <li>The individual is not a candidate for either the following procedures:\t\t<ol> <li>Deep brain stimulation (DBS); or</li> <li>Radiofrequency (RF) thermoablation;<br/> and</li> </ol> </li> <li>The absence of all of the following conditions:\t\t<ol> <li>Central neurodegenerative disease other than Parkinson\u2019s Disease (includes multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer\u2019s disease); or</li> <li>Previous deep brain stimulation; or</li> <li>Previous basal ganglia ablation procedure; or</li> <li>Coagulopathy or current anticoagulant use which cannot be reversed; or</li> <li>Intracranial tumor with significant anatomic distortion.</li> </ol> </li> </ol> </li>\n<li>Age 30 or older; and</li>\n<li>Unilateral pallidotomy is used as an adjunct to medication treatment of idiopathic Parkinson\u2019s disease; and</li>\n<li>Levodopa responsive (as defined by a 30% or greater reduction in the Movement Disorder Society- Unified Parkinson's Disease Rating Scale [MDS-UPDRS] motor subscale in the on versus off levodopa medication state; and</li>\n<li>Moderate-to-severe motor complications as defined by at least one of the following:\t\t<ol> <li>MDS-UPDRS score of 20 or greater in the meds off condition; or</li> <li>Motor complications on optimum medical treatment documented by at least one of the following:\t\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Dyskinesia (as defined by MDS-UPDRS item 4.2 score of 2 or greater in the meds on condition); or</li> <li>Motor fluctuations (as defined by MDS-UPDRS item 4.4 score of 2 or greater);<br/> and </li> </ol> </li> </ol> </li>\n<li>MDS-UPDRS score of 20 or greater in the meds off condition; or</li>\n<li>Motor complications on optimum medical treatment documented by at least one of the following:\t\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Dyskinesia (as defined by MDS-UPDRS item 4.2 score of 2 or greater in the meds on condition); or</li> <li>Motor fluctuations (as defined by MDS-UPDRS item 4.4 score of 2 or greater);<br/> and </li> </ol> </li>\n<li>Dyskinesia (as defined by MDS-UPDRS item 4.2 score of 2 or greater in the meds on condition); or</li>\n<li>Motor fluctuations (as defined by MDS-UPDRS item 4.4 score of 2 or greater);<br/> and </li>\n<li>The individual is not a candidate for either the following procedures:\t\t<ol> <li>Deep brain stimulation (DBS); or</li> <li>Radiofrequency (RF) thermoablation;<br/> and</li> </ol> </li>\n<li>Deep brain stimulation (DBS); or</li>\n<li>Radiofrequency (RF) thermoablation;<br/> and</li>\n<li>The absence of all of the following conditions:\t\t<ol> <li>Central neurodegenerative disease other than Parkinson\u2019s Disease (includes multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer\u2019s disease); or</li> <li>Previous deep brain stimulation; or</li> <li>Previous basal ganglia ablation procedure; or</li> <li>Coagulopathy or current anticoagulant use which cannot be reversed; or</li> <li>Intracranial tumor with significant anatomic distortion.</li> </ol> </li>\n<li>Central neurodegenerative disease other than Parkinson\u2019s Disease (includes multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer\u2019s disease); or</li>\n<li>Previous deep brain stimulation; or</li>\n<li>Previous basal ganglia ablation procedure; or</li>\n<li>Coagulopathy or current anticoagulant use which cannot be reversed; or</li>\n<li>Intracranial tumor with significant anatomic distortion.</li>\nInvestigational and Not Medically Necessary:\nMRI guided high intensity focused ultrasound ablation is considered investigational and not medically necessary when the criteria above are not met and for all other non-oncologic indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Unilateral focused ultrasound thalamotomy",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Unilateral focused ultrasound thalamotomy is considered medically necessary for the treatment of adults with essential tremors when all of the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Moderate to severe tremor of the hand (as defined by a score of 2 or greater on the clinical rating scale for tremor [CRST])",
                  "conditions": null
                },
                {
                  "desc": "Failure of 2 or more tremor suppressant medications, as evidenced by persistent moderate to severe tremors, intolerable side effects of drug therapy or contraindications",
                  "conditions": null
                },
                {
                  "desc": "At least 1 of the medications failed was a first line agent (propranolol or primidone)",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Unilateral focused ultrasound pallidotomy",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Unilateral focused ultrasound pallidotomy is considered medically necessary for the treatment of idiopathic Parkinson\u2019s disease in individuals who meet all of the following criteria:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Age 30 or older",
                  "conditions": null
                },
                {
                  "desc": "Unilateral pallidotomy is used as an adjunct to medication treatment of idiopathic Parkinson\u2019s disease",
                  "conditions": null
                },
                {
                  "desc": "Levodopa responsive (as defined by a 30% or greater reduction in the Movement Disorder Society- Unified Parkinson's Disease Rating Scale [MDS-UPDRS] motor subscale in the on versus off levodopa medication state)",
                  "conditions": null
                },
                {
                  "desc": "Moderate-to-severe motor complications as defined by at least one of the following:",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "MDS-UPDRS score of 20 or greater in the meds off condition",
                        "conditions": null
                      },
                      {
                        "desc": "Motor complications on optimum medical treatment documented by at least one of the following:",
                        "conditions": {
                          "ANY": [
                            {
                              "desc": "Dyskinesia (as defined by MDS-UPDRS item 4.2 score of 2 or greater in the meds on condition)",
                              "conditions": null
                            },
                            {
                              "desc": "Motor fluctuations (as defined by MDS-UPDRS item 4.4 score of 2 or greater)",
                              "conditions": null
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "desc": "The individual is not a candidate for either the following procedures:",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Deep brain stimulation (DBS)",
                        "conditions": null
                      },
                      {
                        "desc": "Radiofrequency (RF) thermoablation",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "The absence of all of the following conditions:",
                  "conditions": {
                    "ALL": [
                      {
                        "desc": "Central neurodegenerative disease other than Parkinson\u2019s Disease (includes multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer\u2019s disease)",
                        "conditions": null
                      },
                      {
                        "desc": "Previous deep brain stimulation",
                        "conditions": null
                      },
                      {
                        "desc": "Previous basal ganglia ablation procedure",
                        "conditions": null
                      },
                      {
                        "desc": "Coagulopathy or current anticoagulant use which cannot be reversed",
                        "conditions": null
                      },
                      {
                        "desc": "Intracranial tumor with significant anatomic distortion",
                        "conditions": null
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "MRI guided high intensity focused ultrasound ablation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "MRI guided high intensity focused ultrasound ablation is considered investigational and not medically necessary when the criteria above are not met and for all other non-oncologic indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 3377,
          "prompt_tokens": 2400,
          "completion_tokens": 977,
          "total_cost": 0.026654999999999998,
          "processing_time": 19.488871097564697
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_d097547.html",
    "subject": "Surface Electromyography and Electrodermal Activity Sensor Devices for Seizure Monitoring",
    "document_number": "MED.00130",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of surface electromyography (sEMG) or electrodermal activity sensor devices for seizure monitoring is considered <strong>investigational and not medically necessary</strong>.</p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of surface electromyography (sEMG) or electrodermal activity sensor devices for seizure monitoring is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "surface electromyography (sEMG) or electrodermal activity sensor devices for seizure monitoring",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of surface electromyography (sEMG) or electrodermal activity sensor devices for seizure monitoring is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 950,
          "prompt_tokens": 852,
          "completion_tokens": 98,
          "total_cost": 0.00573,
          "processing_time": 3.6048710346221924
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e001421.html",
    "subject": "Wearable Devices for Stress Relief and Management",
    "document_number": "MED.00138",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Wearable devices for management, monitoring or prevention of stress and stress-related conditions are considered <strong>investigational and not medically necessary</strong> for all indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nWearable devices for management, monitoring or prevention of stress and stress-related conditions are considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Wearable devices for management, monitoring or prevention of stress and stress-related conditions",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Wearable devices for management, monitoring or prevention of stress and stress-related conditions are considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 938,
          "prompt_tokens": 848,
          "completion_tokens": 90,
          "total_cost": 0.0055899999999999995,
          "processing_time": 1.993466854095459
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_d092916.html",
    "subject": "Gene Therapy for Spinal Muscular Atrophy",
    "document_number": "MED.00129",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p style=\"margin-bottom:8px\"><strong>Medically Necessary:</strong></p>\n<p>A one-time infusion of onasemnogene abeparvovec-xioi is considered <strong>medically necessary</strong> in individuals with spinal muscular atrophy (SMA) when <strong>all</strong> of the following criteria are met:</p>\n<li>Confirmed SMA diagnosis as documented by a bi-allelic SMN1 5q gene variant or deletions and <em>either </em>of the following:\t<ol>\t\t<li>No more than 3 copies of SMN2; <strong>or</strong></li>\t\t<li>Onset of SMA-associated signs and symptoms before 6 months of age; <strong>and </strong></li>\t</ol>\t</li>\n<li>No more than 3 copies of SMN2; <strong>or</strong></li>\n<li>Onset of SMA-associated signs and symptoms before 6 months of age; <strong>and </strong></li>\n<li>Two years of age or younger at the time of vector infusion; <strong>and</strong></li>\n<li>Anti-adeno-associated viral vector, serotype 9 (AAV9) antibody titer less than or equal to 1:50;<strong> and</strong></li>\n<li>No use of invasive ventilatory support (tracheotomy with positive pressure) or use of non-invasive ventilator support (BiPAP) for more than 16 hours per day as a result of advanced SMA disease; <strong>and</strong></li>\n<li>No serious concomitant illness (for example, severe liver or kidney disease, symptomatic cardiomyopathy, active viral infection).</li>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Onasemnogene abeparvovec-xioi is considered <strong>investigational and not medically necessary</strong> when the criteria above are not met, including for repeat infusions, and for all other indications.</p>",
    "content": "Medically Necessary:\nA one-time infusion of onasemnogene abeparvovec-xioi is considered medically necessary in individuals with spinal muscular atrophy (SMA) when all of the following criteria are met:\n<li>Confirmed SMA diagnosis as documented by a bi-allelic SMN1 5q gene variant or deletions and either of the following:\t<ol> <li>No more than 3 copies of SMN2; or</li> <li>Onset of SMA-associated signs and symptoms before 6 months of age; and </li> </ol> </li>\n<li>No more than 3 copies of SMN2; or</li>\n<li>Onset of SMA-associated signs and symptoms before 6 months of age; and </li>\n<li>Two years of age or younger at the time of vector infusion; and</li>\n<li>Anti-adeno-associated viral vector, serotype 9 (AAV9) antibody titer less than or equal to 1:50; and</li>\n<li>No use of invasive ventilatory support (tracheotomy with positive pressure) or use of non-invasive ventilator support (BiPAP) for more than 16 hours per day as a result of advanced SMA disease; and</li>\n<li>No serious concomitant illness (for example, severe liver or kidney disease, symptomatic cardiomyopathy, active viral infection).</li>\nInvestigational and Not Medically Necessary:\nOnasemnogene abeparvovec-xioi is considered investigational and not medically necessary when the criteria above are not met, including for repeat infusions, and for all other indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "One-time infusion of onasemnogene abeparvovec-xioi",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A one-time infusion of onasemnogene abeparvovec-xioi is considered medically necessary in individuals with spinal muscular atrophy (SMA) when all of the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Confirmed SMA diagnosis as documented by a bi-allelic SMN1 5q gene variant or deletions and either of the following:",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "No more than 3 copies of SMN2",
                        "conditions": null
                      },
                      {
                        "desc": "Onset of SMA-associated signs and symptoms before 6 months of age",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "No more than 3 copies of SMN2",
                  "conditions": null
                },
                {
                  "desc": "Onset of SMA-associated signs and symptoms before 6 months of age",
                  "conditions": null
                },
                {
                  "desc": "Two years of age or younger at the time of vector infusion",
                  "conditions": null
                },
                {
                  "desc": "Anti-adeno-associated viral vector, serotype 9 (AAV9) antibody titer less than or equal to 1:50",
                  "conditions": null
                },
                {
                  "desc": "No use of invasive ventilatory support (tracheotomy with positive pressure) or use of non-invasive ventilator support (BiPAP) for more than 16 hours per day as a result of advanced SMA disease",
                  "conditions": null
                },
                {
                  "desc": "No serious concomitant illness (for example, severe liver or kidney disease, symptomatic cardiomyopathy, active viral infection)",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Onasemnogene abeparvovec-xioi",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Onasemnogene abeparvovec-xioi is considered investigational and not medically necessary when the criteria above are not met, including for repeat infusions, and for all other indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1654,
          "prompt_tokens": 1150,
          "completion_tokens": 504,
          "total_cost": 0.013309999999999999,
          "processing_time": 6.539597749710083
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e002509.html",
    "subject": "Gene Therapy for Duchenne Muscular Dystrophy",
    "document_number": "MED.00144",
    "publish_date": "12/28/2023",
    "status": "New",
    "last_review_date": "08/10/2023",
    "html_content": "<p style=\"margin-right:-61px\"><strong>Medically Necessary:</strong></p>\n<p style=\"margin-right:-26px\">A one-time infusion of<strong> </strong>delandistrogene moxeparvovec-rokl (ELEVIDYS) is considered <strong>medically necessary</strong> in individuals who meet <strong>all </strong>of the following criteria:</p>\n<li>Diagnosis of Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene; <strong>and</strong></li>\n<li>No deletion in exon 8 or exon 9 in DMD gene; <strong>and </strong></li>\n<li>Ambulatory; <strong>and</strong></li>\n<li>Age 4 through 5 years (at least 4 years 0 days and less than 6 years old); <strong>and</strong></li>\n<li>Anti-AAVrh74 total binding antibody titers less than 1:400; <strong>and</strong></li>\n<li>Absence of active infection; <strong>and</strong></li>\n<li>Absence of significant liver dysfunction or disease, defined as <em>at least one of the following</em>:\t<ol>\t\t<li>Preexisting liver impairment; <strong>or</strong></li>\t\t<li>Chronic hepatic condition; <strong>or</strong></li>\t\t<li>Acute liver disease (e.g., acute hepatic viral infection).</li>\t</ol>\t</li>\n<li>Preexisting liver impairment; <strong>or</strong></li>\n<li>Chronic hepatic condition; <strong>or</strong></li>\n<li>Acute liver disease (e.g., acute hepatic viral infection).</li>\n<p style=\"margin-right:-61px\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Delandistrogene moxeparvovec-rokl is considered <strong>investigational and not medically necessary</strong><strong>&nbsp;</strong>when the criteria above are not met.</p>",
    "content": "Medically Necessary:\nA one-time infusion of delandistrogene moxeparvovec-rokl (ELEVIDYS) is considered medically necessary in individuals who meet all of the following criteria:\n<li>Diagnosis of Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene; and</li>\n<li>No deletion in exon 8 or exon 9 in DMD gene; and </li>\n<li>Ambulatory; and</li>\n<li>Age 4 through 5 years (at least 4 years 0 days and less than 6 years old); and</li>\n<li>Anti-AAVrh74 total binding antibody titers less than 1:400; and</li>\n<li>Absence of active infection; and</li>\n<li>Absence of significant liver dysfunction or disease, defined as at least one of the following:\t<ol> <li>Preexisting liver impairment; or</li> <li>Chronic hepatic condition; or</li> <li>Acute liver disease (e.g., acute hepatic viral infection).</li> </ol> </li>\n<li>Preexisting liver impairment; or</li>\n<li>Chronic hepatic condition; or</li>\n<li>Acute liver disease (e.g., acute hepatic viral infection).</li>\nInvestigational and Not Medically Necessary:\nDelandistrogene moxeparvovec-rokl is considered investigational and not medically necessary\u00a0when the criteria above are not met.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Delandistrogene moxeparvovec-rokl (ELEVIDYS) infusion",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A one-time infusion of delandistrogene moxeparvovec-rokl (ELEVIDYS) is considered medically necessary in individuals who meet all of the following criteria:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Diagnosis of Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene",
                  "conditions": null
                },
                {
                  "desc": "No deletion in exon 8 or exon 9 in DMD gene",
                  "conditions": null
                },
                {
                  "desc": "Ambulatory",
                  "conditions": null
                },
                {
                  "desc": "Age 4 through 5 years (at least 4 years 0 days and less than 6 years old)",
                  "conditions": null
                },
                {
                  "desc": "Anti-AAVrh74 total binding antibody titers less than 1:400",
                  "conditions": null
                },
                {
                  "desc": "Absence of active infection",
                  "conditions": null
                },
                {
                  "desc": "Absence of significant liver dysfunction or disease, defined as at least one of the following:",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Preexisting liver impairment",
                        "conditions": null
                      },
                      {
                        "desc": "Chronic hepatic condition",
                        "conditions": null
                      },
                      {
                        "desc": "Acute liver disease (e.g., acute hepatic viral infection)",
                        "conditions": null
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "Delandistrogene moxeparvovec-rokl (ELEVIDYS) infusion",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Delandistrogene moxeparvovec-rokl is considered investigational and not medically necessary when the criteria above are not met.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1573,
          "prompt_tokens": 1122,
          "completion_tokens": 451,
          "total_cost": 0.012375,
          "processing_time": 7.261971950531006
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a070642.html",
    "subject": "Low-Frequency Ultrasound Therapy for Wound Management",
    "document_number": "MED.00096",
    "publish_date": "09/27/2023",
    "status": "Reviewed",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Use of low-frequency, non-contact, non-thermal, ultrasound therapy is considered <strong>investigational and not medically necessary </strong>for all applications.</p>",
    "content": "Investigational and Not Medically Necessary:\nUse of low-frequency, non-contact, non-thermal, ultrasound therapy is considered investigational and not medically necessary for all applications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Use of low-frequency, non-contact, non-thermal, ultrasound therapy",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Use of low-frequency, non-contact, non-thermal, ultrasound therapy is considered investigational and not medically necessary for all applications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 935,
          "prompt_tokens": 847,
          "completion_tokens": 88,
          "total_cost": 0.005555,
          "processing_time": 3.1598939895629883
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e001866.html",
    "subject": "High-volume Colonic Irrigation",
    "document_number": "MED.00141",
    "publish_date": "09/27/2023",
    "status": "Reviewed",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>High-volume colonic irrigation is considered <strong>investigational and not medically necessary</strong> for all indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nHigh-volume colonic irrigation is considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "High-volume colonic irrigation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "High-volume colonic irrigation is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 908,
          "prompt_tokens": 838,
          "completion_tokens": 70,
          "total_cost": 0.00524,
          "processing_time": 1.670954942703247
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050521.html",
    "subject": "Quantitative Sensory Testing",
    "document_number": "MED.00082",
    "publish_date": "09/27/2023",
    "status": "Reviewed",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Quantitative sensory testing including, but not limited to current perception threshold testing, also known as sensory nerve conduction threshold testing, and pressure-specified sensory device testing is considered <strong>investigational and not medically necessary.</strong></p>",
    "content": "Investigational and Not Medically Necessary:\nQuantitative sensory testing including, but not limited to current perception threshold testing, also known as sensory nerve conduction threshold testing, and pressure-specified sensory device testing is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Quantitative sensory testing",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Quantitative sensory testing including, but not limited to current perception threshold testing, also known as sensory nerve conduction threshold testing, and pressure-specified sensory device testing is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 953,
          "prompt_tokens": 861,
          "completion_tokens": 92,
          "total_cost": 0.005685,
          "processing_time": 1.9802391529083252
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050526.html",
    "subject": "Quantitative Muscle Testing Devices",
    "document_number": "MED.00089",
    "publish_date": "09/27/2023",
    "status": "Reviewed",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of quantitative muscle testing devices is considered <strong>investigational and not medically necessary.</strong></p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of quantitative muscle testing devices is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Use of quantitative muscle testing devices",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of quantitative muscle testing devices is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 907,
          "prompt_tokens": 837,
          "completion_tokens": 70,
          "total_cost": 0.005235,
          "processing_time": 1.5776841640472412
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c117100.html",
    "subject": "Automated Evacuation of Meibomian Gland",
    "document_number": "MED.00103",
    "publish_date": "09/27/2023",
    "status": "Reviewed",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of an automated evacuation device using heat and intermittent pressure, and associated tear film imaging, is considered <strong>investigational and not medically necessary </strong>for the treatment of meibomian gland dysfunction.</p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of an automated evacuation device using heat and intermittent pressure, and associated tear film imaging, is considered investigational and not medically necessary for the treatment of meibomian gland dysfunction.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "The use of an automated evacuation device using heat and intermittent pressure, and associated tear film imaging",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of an automated evacuation device using heat and intermittent pressure, and associated tear film imaging, is considered investigational and not medically necessary for the treatment of meibomian gland dysfunction.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 963,
          "prompt_tokens": 859,
          "completion_tokens": 104,
          "total_cost": 0.005855,
          "processing_time": 1.8826889991760254
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e002213.html",
    "subject": "Digital Therapy Devices for Treatment of Amblyopia",
    "document_number": "MED.00145",
    "publish_date": "09/27/2023",
    "status": "Reviewed",
    "last_review_date": "05/11/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Digital therapy devices for treatment of amblyopia are considered <strong>investigational and not medically necessary</strong>.</p>",
    "content": "Investigational and Not Medically Necessary:\nDigital therapy devices for treatment of amblyopia are considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Digital therapy devices for treatment of amblyopia",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Digital therapy devices for treatment of amblyopia are considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 914,
          "prompt_tokens": 839,
          "completion_tokens": 75,
          "total_cost": 0.00532,
          "processing_time": 1.4057042598724365
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e000640.html",
    "subject": "Non-invasive Heart Failure and Arrhythmia Management and Monitoring System",
    "document_number": "MED.00134",
    "publish_date": "09/27/2023",
    "status": "Reviewed",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of a non-invasive heart failure and arrhythmia management and monitoring system (for example, \u00b5-Cor\u2122 Heart Failure and Arrhythmia Management System) is considered <strong>investigational and not medically necessary</strong> for all indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of a non-invasive heart failure and arrhythmia management and monitoring system (for example, \u00b5-Cor\u2122 Heart Failure and Arrhythmia Management System) is considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Use of a non-invasive heart failure and arrhythmia management and monitoring system",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of a non-invasive heart failure and arrhythmia management and monitoring system (for example, \u00b5-Cor\u2122 Heart Failure and Arrhythmia Management System) is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 974,
          "prompt_tokens": 866,
          "completion_tokens": 108,
          "total_cost": 0.0059499999999999996,
          "processing_time": 2.137491226196289
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e002527.html",
    "subject": "Cellular Therapy Products for Allogeneic Stem Cell Transplantation",
    "document_number": "MED.00147",
    "publish_date": "09/27/2023",
    "status": "New",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>Use of ex-vivo expansion of cord blood stem cell products (for example, omidubicel) is considered <strong>medically necessary </strong>for individuals when the following criteria are met:</p>\n<li>12 years of age or older; <strong>and</strong></li>\n<li>Is a candidate for myeloablative allogeneic hematopoietic stem cell transplantation to treat a hematologic malignancy; <strong>and</strong></li>\n<li>The appropriate stem cell transplant criteria are met (see related policies above); <strong>and</strong></li>\n<li>Is eligible and planned for umbilical cord blood transplantation following myeloablative conditioning; <strong>and</strong></li>\n<li>Use is intended to reduce the time to neutrophil recovery and the incidence of infection.</li>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Use of ex-vivo expansion of cord blood stem cell products (for example, omidubicel) is considered <strong>investigational and not medically necessary </strong>when the criteria above are not met and<strong> </strong>for all other indications.</p>",
    "content": "Medically Necessary:\nUse of ex-vivo expansion of cord blood stem cell products (for example, omidubicel) is considered medically necessary for individuals when the following criteria are met:\n<li>12 years of age or older; and</li>\n<li>Is a candidate for myeloablative allogeneic hematopoietic stem cell transplantation to treat a hematologic malignancy; and</li>\n<li>The appropriate stem cell transplant criteria are met (see related policies above); and</li>\n<li>Is eligible and planned for umbilical cord blood transplantation following myeloablative conditioning; and</li>\n<li>Use is intended to reduce the time to neutrophil recovery and the incidence of infection.</li>\nInvestigational and Not Medically Necessary:\nUse of ex-vivo expansion of cord blood stem cell products (for example, omidubicel) is considered investigational and not medically necessary when the criteria above are not met and for all other indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Use of ex-vivo expansion of cord blood stem cell products (for example, omidubicel)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Use of ex-vivo expansion of cord blood stem cell products (for example, omidubicel) is considered medically necessary for individuals when the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "12 years of age or older",
                  "conditions": null
                },
                {
                  "desc": "Is a candidate for myeloablative allogeneic hematopoietic stem cell transplantation to treat a hematologic malignancy",
                  "conditions": null
                },
                {
                  "desc": "The appropriate stem cell transplant criteria are met (see related policies above)",
                  "conditions": null
                },
                {
                  "desc": "Is eligible and planned for umbilical cord blood transplantation following myeloablative conditioning",
                  "conditions": null
                },
                {
                  "desc": "Use is intended to reduce the time to neutrophil recovery and the incidence of infection",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Use of ex-vivo expansion of cord blood stem cell products (for example, omidubicel)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Use of ex-vivo expansion of cord blood stem cell products (for example, omidubicel) is considered investigational and not medically necessary when the criteria above are not met and for all other indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1367,
          "prompt_tokens": 1011,
          "completion_tokens": 356,
          "total_cost": 0.010394999999999998,
          "processing_time": 6.273910045623779
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e000514.html",
    "subject": "Adipose-derived Regenerative Cell Therapy and Soft Tissue Augmentation Procedures",
    "document_number": "MED.00132",
    "publish_date": "06/28/2023",
    "status": "Revised",
    "last_review_date": "05/11/2023",
    "html_content": "<p><strong>I.&nbsp; Autologous Adipose-derived Regenerative Cell Therapy:</strong></p>\n<li>Autologous adipose-derived regenerative cell therapy (for example, Lipogems) is considered <strong>investigational and not medically necessary</strong> for all indications.</li>\n<p><strong>II.&nbsp;&nbsp;Autologous Fat Grafting:</strong></p>\n<p>Autologous fat grafting is considered <strong>medically necessary</strong> when both of the following criteria have been met:</p>\n<li>There is documented evidence of significant functional impairment: <strong>and</strong></li>\n<li>The procedure can be reasonably expected to improve the functional impairment.</li>\n<p>Autologous fat grafting is considered <strong>reconstructive</strong> when there is a significant variation from normal related to <em>any</em> of the following:</p>\n<li>Accidental injury; <strong>or</strong></li>\n<li>Disease; <strong>or</strong></li>\n<li>Trauma; <strong>or</strong></li>\n<li>Treatment of a disease or congenital defect (for example, for breast contouring following breast reconstruction procedures).</li>\n<p>Autologous fat grafting is considered <strong>cosmetic and not medically necessary</strong> when the criteria above have not been met, including for:</p>\n<li>Performed in the absence of a significant functional impairment; <strong>or</strong>,</li>\n<li>Is not reconstructive; <strong>or</strong></li>\n<li>Is intended to change a physical appearance that would be considered within normal human anatomic variation.</li>\n<p style=\"text-align:justify\"><strong>III.&nbsp;&nbsp;Injectable Soft Tissue Fillers </strong>(for example:<strong> </strong>poly-L-lactic acid [PLLA], synthetic calcium hydroxylapatite, hyaluronic acid, or collagen)</p>\n<p style=\"text-align:justify\">Use of injectable soft tissue fillers is considered <strong>medically necessary</strong> when both of the following criteria have been met:</p>\n<li>There is documented evidence of significant functional impairment; <strong>and</strong></li>\n<li>The procedure can be reasonably expected to improve the functional impairment.</li>\n<p>Use of injectable soft tissue fillers is considered <strong>reconstructive</strong> when there is a significant variation from normal related to <em>any </em>of the following:</p>\n<li>Accidental injury; <strong>or</strong></li>\n<li>Disease; <strong>or</strong></li>\n<li>Trauma; <strong>or</strong></li>\n<li>Treatment of a disease or congenital defect.</li>\n<p>Use of injectable soft tissue fillers is considered <strong>cosmetic and not medically necessary </strong>the criteria above have not been met, including when:</p>\n<li>Performed in the absence of a significant functional impairment; <strong>or</strong></li>\n<li>Not reconstructive; <strong>or</strong></li>\n<li>Intended to change a physical appearance that would be considered within normal human anatomic variation (for example: lip enhancement procedures).</li>",
    "content": "I.\u00a0 Autologous Adipose-derived Regenerative Cell Therapy:\n<li>Autologous adipose-derived regenerative cell therapy (for example, Lipogems) is considered investigational and not medically necessary for all indications.</li>\nII.\u00a0\u00a0Autologous Fat Grafting:\nAutologous fat grafting is considered medically necessary when both of the following criteria have been met:\n<li>There is documented evidence of significant functional impairment: and</li>\n<li>The procedure can be reasonably expected to improve the functional impairment.</li>\nAutologous fat grafting is considered reconstructive when there is a significant variation from normal related to any of the following:\n<li>Accidental injury; or</li>\n<li>Disease; or</li>\n<li>Trauma; or</li>\n<li>Treatment of a disease or congenital defect (for example, for breast contouring following breast reconstruction procedures).</li>\nAutologous fat grafting is considered cosmetic and not medically necessary when the criteria above have not been met, including for:\n<li>Performed in the absence of a significant functional impairment; or,</li>\n<li>Is not reconstructive; or</li>\n<li>Is intended to change a physical appearance that would be considered within normal human anatomic variation.</li>\nIII.\u00a0\u00a0Injectable Soft Tissue Fillers (for example: poly-L-lactic acid [PLLA], synthetic calcium hydroxylapatite, hyaluronic acid, or collagen)\nUse of injectable soft tissue fillers is considered medically necessary when both of the following criteria have been met:\n<li>There is documented evidence of significant functional impairment; and</li>\n<li>The procedure can be reasonably expected to improve the functional impairment.</li>\nUse of injectable soft tissue fillers is considered reconstructive when there is a significant variation from normal related to any of the following:\n<li>Accidental injury; or</li>\n<li>Disease; or</li>\n<li>Trauma; or</li>\n<li>Treatment of a disease or congenital defect.</li>\nUse of injectable soft tissue fillers is considered cosmetic and not medically necessary the criteria above have not been met, including when:\n<li>Performed in the absence of a significant functional impairment; or</li>\n<li>Not reconstructive; or</li>\n<li>Intended to change a physical appearance that would be considered within normal human anatomic variation (for example: lip enhancement procedures).</li>",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Autologous Adipose-derived Regenerative Cell Therapy",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous adipose-derived regenerative cell therapy (for example, Lipogems) is considered investigational and not medically necessary for all indications.",
            "conditions": null
          },
          {
            "medical_act": "Autologous Fat Grafting",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Autologous fat grafting is considered medically necessary when both of the following criteria have been met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "There is documented evidence of significant functional impairment",
                  "conditions": null
                },
                {
                  "desc": "The procedure can be reasonably expected to improve the functional impairment",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Autologous Fat Grafting",
            "sub_medical_act": null,
            "necessity_type": "Reconstructive",
            "description": "Autologous fat grafting is considered reconstructive when there is a significant variation from normal related to any of the following:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Accidental injury",
                  "conditions": null
                },
                {
                  "desc": "Disease",
                  "conditions": null
                },
                {
                  "desc": "Trauma",
                  "conditions": null
                },
                {
                  "desc": "Treatment of a disease or congenital defect (for example, for breast contouring following breast reconstruction procedures)",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Autologous Fat Grafting",
            "sub_medical_act": null,
            "necessity_type": "Cosmetic and Not Medically Necessary",
            "description": "Autologous fat grafting is considered cosmetic and not medically necessary when the criteria above have not been met, including for:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Performed in the absence of a significant functional impairment",
                  "conditions": null
                },
                {
                  "desc": "Is not reconstructive",
                  "conditions": null
                },
                {
                  "desc": "Is intended to change a physical appearance that would be considered within normal human anatomic variation",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Injectable Soft Tissue Fillers",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Use of injectable soft tissue fillers is considered medically necessary when both of the following criteria have been met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "There is documented evidence of significant functional impairment",
                  "conditions": null
                },
                {
                  "desc": "The procedure can be reasonably expected to improve the functional impairment",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Injectable Soft Tissue Fillers",
            "sub_medical_act": null,
            "necessity_type": "Reconstructive",
            "description": "Use of injectable soft tissue fillers is considered reconstructive when there is a significant variation from normal related to any of the following:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Accidental injury",
                  "conditions": null
                },
                {
                  "desc": "Disease",
                  "conditions": null
                },
                {
                  "desc": "Trauma",
                  "conditions": null
                },
                {
                  "desc": "Treatment of a disease or congenital defect",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Injectable Soft Tissue Fillers",
            "sub_medical_act": null,
            "necessity_type": "Cosmetic and Not Medically Necessary",
            "description": "Use of injectable soft tissue fillers is considered cosmetic and not medically necessary when the criteria above have not been met, including when:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Performed in the absence of a significant functional impairment",
                  "conditions": null
                },
                {
                  "desc": "Not reconstructive",
                  "conditions": null
                },
                {
                  "desc": "Intended to change a physical appearance that would be considered within normal human anatomic variation (for example: lip enhancement procedures)",
                  "conditions": null
                }
              ]
            }
          }
        ],
        "usage": {
          "total_tokens": 2237,
          "prompt_tokens": 1303,
          "completion_tokens": 934,
          "total_cost": 0.020525,
          "processing_time": 14.606947183609009
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e000517.html",
    "subject": "Ingestion Event Monitors",
    "document_number": "MED.00133",
    "publish_date": "06/28/2023",
    "status": "Reviewed",
    "last_review_date": "05/11/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Ingestion event monitors are considered <strong>investigational and not medically necessary</strong> for medication monitoring and adherence and for all other indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nIngestion event monitors are considered investigational and not medically necessary for medication monitoring and adherence and for all other indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Ingestion event monitors",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Ingestion event monitors are considered investigational and not medically necessary for medication monitoring and adherence and for all other indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 919,
          "prompt_tokens": 844,
          "completion_tokens": 75,
          "total_cost": 0.005345,
          "processing_time": 1.5798530578613281
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_c129400.html",
    "subject": "Bioimpedance Spectroscopy Devices for the Detection and Management of Lymphedema",
    "document_number": "MED.00105",
    "publish_date": "06/28/2023",
    "status": "Reviewed",
    "last_review_date": "05/11/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of bioimpedance spectroscopy testing in the assessment, diagnosis, or management of individuals with known or suspected lymphedema is considered <strong>investigational and not medically necessary.</strong></p>",
    "content": "Investigational and Not Medically Necessary:\nThe use of bioimpedance spectroscopy testing in the assessment, diagnosis, or management of individuals with known or suspected lymphedema is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Bioimpedance Spectroscopy Testing",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of bioimpedance spectroscopy testing in the assessment, diagnosis, or management of individuals with known or suspected lymphedema is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 947,
          "prompt_tokens": 857,
          "completion_tokens": 90,
          "total_cost": 0.005634999999999999,
          "processing_time": 1.4597551822662354
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e001135.html",
    "subject": "Eye Movement Analysis Using Non-spatial Calibration for the Diagnosis of Concussion",
    "document_number": "MED.00137",
    "publish_date": "06/28/2023",
    "status": "Reviewed",
    "last_review_date": "05/11/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Eye movement analysis using non-spatial calibration is considered <strong>investigational and not medically necessary</strong> for the diagnosis of concussion.</p>",
    "content": "Investigational and Not Medically Necessary:\nEye movement analysis using non-spatial calibration is considered investigational and not medically necessary for the diagnosis of concussion.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Eye movement analysis using non-spatial calibration",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Eye movement analysis using non-spatial calibration is considered investigational and not medically necessary for the diagnosis of concussion.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 921,
          "prompt_tokens": 843,
          "completion_tokens": 78,
          "total_cost": 0.005385,
          "processing_time": 1.4101488590240479
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050527.html",
    "subject": "Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders",
    "document_number": "MED.00090",
    "publish_date": "06/28/2023",
    "status": "Revised",
    "last_review_date": "05/11/2023",
    "html_content": "<p style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>A wireless capsule (SmartPill Motility Testing System) is considered <strong>investigational and not medically necessary </strong>for evaluation of all conditions including, but not limited to the following:</p>\n<li>Suspected gastric motility disorders; <strong>or</strong></li>\n<li>Suspected intestinal motility disorders.</li>",
    "content": "Investigational and Not Medically Necessary:\nA wireless capsule (SmartPill Motility Testing System) is considered investigational and not medically necessary for evaluation of all conditions including, but not limited to the following:\n<li>Suspected gastric motility disorders; or</li>\n<li>Suspected intestinal motility disorders.</li>",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Wireless Capsule (SmartPill Motility Testing System)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A wireless capsule (SmartPill Motility Testing System) is considered investigational and not medically necessary for evaluation of all conditions including, but not limited to the following:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Suspected gastric motility disorders",
                  "conditions": null
                },
                {
                  "desc": "Suspected intestinal motility disorders",
                  "conditions": null
                }
              ]
            }
          }
        ],
        "usage": {
          "total_tokens": 1015,
          "prompt_tokens": 879,
          "completion_tokens": 136,
          "total_cost": 0.006435000000000001,
          "processing_time": 3.1719560623168945
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_b091194.html",
    "subject": "Hyperoxemic Reperfusion Therapy",
    "document_number": "MED.00098",
    "publish_date": "06/28/2023",
    "status": "Reviewed",
    "last_review_date": "05/11/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Use of hyperoxemic reperfusion therapy is considered <strong>investigational and not medically necessary</strong> for all indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nUse of hyperoxemic reperfusion therapy is considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Use of hyperoxemic reperfusion therapy",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Use of hyperoxemic reperfusion therapy is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 917,
          "prompt_tokens": 841,
          "completion_tokens": 76,
          "total_cost": 0.005344999999999999,
          "processing_time": 1.8893489837646484
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a050480.html",
    "subject": "Parenteral Antibiotics for the Treatment of Lyme Disease",
    "document_number": "MED.00013",
    "publish_date": "06/28/2023",
    "status": "Revised",
    "last_review_date": "05/11/2023",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>A course of up to 4 weeks of intravenous (IV) antibiotic therapy is considered <strong>medically necessary</strong> for individuals with Lyme disease meeting ANY of the following criteria:</p>\n<ul>\t<li>Myocarditis associated with second- or third-degree atrioventricular block, or with first-degree heart block when the PR interval is prolonged to 300 milliseconds or greater; <strong>or</strong></li>\t<li>Persistent or recurrent joint swelling (that is, arthritis) after an initial 1 month trial of oral antibiotics; <strong>or</strong></li>\t<li>Acute or chronic neurological disease affecting the central or peripheral nervous system, including ANY of the following:\t<ul>\t\t<li>Meningitis; <strong>or</strong></li>\t\t<li>Any neurologic syndrome with cerebrospinal fluid (CSF) pleocytosis; <strong>or</strong></li>\t\t<li>Peripheral neurologic syndromes with normal CSF (including radiculopathy, diffuse neuropathy, mononeuropathy multiplex, or cranial neuropathy) if severe or following treatment failure with oral antibiotic therapy; <strong>or</strong></li>\t\t<li>Encephalomyelitis; <strong>or</strong></li>\t\t<li>Encephalopathy.</li>\t</ul>\t</li></ul>\n<li>Myocarditis associated with second- or third-degree atrioventricular block, or with first-degree heart block when the PR interval is prolonged to 300 milliseconds or greater; <strong>or</strong></li>\n<li>Persistent or recurrent joint swelling (that is, arthritis) after an initial 1 month trial of oral antibiotics; <strong>or</strong></li>\n<li>Acute or chronic neurological disease affecting the central or peripheral nervous system, including ANY of the following:\t<ul>\t\t<li>Meningitis; <strong>or</strong></li>\t\t<li>Any neurologic syndrome with cerebrospinal fluid (CSF) pleocytosis; <strong>or</strong></li>\t\t<li>Peripheral neurologic syndromes with normal CSF (including radiculopathy, diffuse neuropathy, mononeuropathy multiplex, or cranial neuropathy) if severe or following treatment failure with oral antibiotic therapy; <strong>or</strong></li>\t\t<li>Encephalomyelitis; <strong>or</strong></li>\t\t<li>Encephalopathy.</li>\t</ul>\t</li>\n<ul>\t\t<li>Meningitis; <strong>or</strong></li>\t\t<li>Any neurologic syndrome with cerebrospinal fluid (CSF) pleocytosis; <strong>or</strong></li>\t\t<li>Peripheral neurologic syndromes with normal CSF (including radiculopathy, diffuse neuropathy, mononeuropathy multiplex, or cranial neuropathy) if severe or following treatment failure with oral antibiotic therapy; <strong>or</strong></li>\t\t<li>Encephalomyelitis; <strong>or</strong></li>\t\t<li>Encephalopathy.</li>\t</ul>\n<li>Meningitis; <strong>or</strong></li>\n<li>Any neurologic syndrome with cerebrospinal fluid (CSF) pleocytosis; <strong>or</strong></li>\n<li>Peripheral neurologic syndromes with normal CSF (including radiculopathy, diffuse neuropathy, mononeuropathy multiplex, or cranial neuropathy) if severe or following treatment failure with oral antibiotic therapy; <strong>or</strong></li>\n<li>Encephalomyelitis; <strong>or</strong></li>\n<li>Encephalopathy.</li>\n<p>And antibiotic used is:</p>\n<ul>\t<li>Ceftriaxone (Rocephin<sup>\u00ae</sup>), cefotaxime (Claforan<sup>\u00ae</sup>), or Penicillin G; <strong>or</strong></li>\t<li>Azithromycin (Zithromax<sup>\u00ae</sup>) in individuals with betalactam allergy or intolerance.</li></ul>\n<li>Ceftriaxone (Rocephin<sup>\u00ae</sup>), cefotaxime (Claforan<sup>\u00ae</sup>), or Penicillin G; <strong>or</strong></li>\n<li>Azithromycin (Zithromax<sup>\u00ae</sup>) in individuals with betalactam allergy or intolerance.</li>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Intravenous (IV) antibiotic therapy for individuals with Lyme disease is considered <strong>investigational and not medically necessary</strong> when criteria are not met, including when the following IV drugs are used:</p>\n<ul>\t<li>Carbapenems (for example, doripenem, ertapenem, imipenem, meropenem); <strong>or</strong></li>\t<li>First-generation cephalosporins (for example, cefazolin); <strong>or</strong></li>\t<li>Fluconazole; <strong>or</strong></li>\t<li>Fluoroquinolones (for example, levofloxacin, moxifloxacin).</li></ul>\n<li>Carbapenems (for example, doripenem, ertapenem, imipenem, meropenem); <strong>or</strong></li>\n<li>First-generation cephalosporins (for example, cefazolin); <strong>or</strong></li>\n<li>Fluconazole; <strong>or</strong></li>\n<li>Fluoroquinolones (for example, levofloxacin, moxifloxacin).</li>\n<p>Other indications for intravenous (IV) antibiotic therapy for Lyme disease are considered <strong>investigational and not medically necessary,</strong> including, but not limited to any of the following:</p>\n<ul>\t<li>Prophylactic treatment of individuals who have reported a tick bite but have no clinical findings suggestive of Lyme disease; <strong>or</strong></li>\t<li>Treatment of individuals with systemic symptoms without serologic or cerebrospinal fluid (CSF) studies confirming Lyme disease; <strong>or</strong></li>\t<li>Treatment of chronic fatigue syndrome or fibromyalgia attributed to Lyme disease; <strong>or</strong></li>\t<li>Initial treatment of Lyme arthritis without coexisting neurological symptoms; <strong>or</strong></li>\t<li>Treatment of persistent Lyme-associated arthritis after 2 prior courses of antibiotic therapy; <strong>or</strong></li>\t<li>Treatment of \u201cpost-Lyme disease\u201d syndrome; <strong>or</strong></li>\t<li>Repeat or prolonged courses (greater than 4 weeks) of intravenous antibiotics.</li></ul>\n<li>Prophylactic treatment of individuals who have reported a tick bite but have no clinical findings suggestive of Lyme disease; <strong>or</strong></li>\n<li>Treatment of individuals with systemic symptoms without serologic or cerebrospinal fluid (CSF) studies confirming Lyme disease; <strong>or</strong></li>\n<li>Treatment of chronic fatigue syndrome or fibromyalgia attributed to Lyme disease; <strong>or</strong></li>\n<li>Initial treatment of Lyme arthritis without coexisting neurological symptoms; <strong>or</strong></li>\n<li>Treatment of persistent Lyme-associated arthritis after 2 prior courses of antibiotic therapy; <strong>or</strong></li>\n<li>Treatment of \u201cpost-Lyme disease\u201d syndrome; <strong>or</strong></li>\n<li>Repeat or prolonged courses (greater than 4 weeks) of intravenous antibiotics.</li>\n<p>Intramuscular antibiotics as a treatment of any aspect of Lyme disease are considered <strong>investigational and not medically necessary.</strong></p>",
    "content": "Medically Necessary:\nA course of up to 4 weeks of intravenous (IV) antibiotic therapy is considered medically necessary for individuals with Lyme disease meeting ANY of the following criteria:\n<ul> <li>Myocarditis associated with second- or third-degree atrioventricular block, or with first-degree heart block when the PR interval is prolonged to 300 milliseconds or greater; or</li> <li>Persistent or recurrent joint swelling (that is, arthritis) after an initial 1 month trial of oral antibiotics; or</li> <li>Acute or chronic neurological disease affecting the central or peripheral nervous system, including ANY of the following:\t<ul> <li>Meningitis; or</li> <li>Any neurologic syndrome with cerebrospinal fluid (CSF) pleocytosis; or</li> <li>Peripheral neurologic syndromes with normal CSF (including radiculopathy, diffuse neuropathy, mononeuropathy multiplex, or cranial neuropathy) if severe or following treatment failure with oral antibiotic therapy; or</li> <li>Encephalomyelitis; or</li> <li>Encephalopathy.</li> </ul> </li></ul>\n<li>Myocarditis associated with second- or third-degree atrioventricular block, or with first-degree heart block when the PR interval is prolonged to 300 milliseconds or greater; or</li>\n<li>Persistent or recurrent joint swelling (that is, arthritis) after an initial 1 month trial of oral antibiotics; or</li>\n<li>Acute or chronic neurological disease affecting the central or peripheral nervous system, including ANY of the following:\t<ul> <li>Meningitis; or</li> <li>Any neurologic syndrome with cerebrospinal fluid (CSF) pleocytosis; or</li> <li>Peripheral neurologic syndromes with normal CSF (including radiculopathy, diffuse neuropathy, mononeuropathy multiplex, or cranial neuropathy) if severe or following treatment failure with oral antibiotic therapy; or</li> <li>Encephalomyelitis; or</li> <li>Encephalopathy.</li> </ul> </li>\n<ul> <li>Meningitis; or</li> <li>Any neurologic syndrome with cerebrospinal fluid (CSF) pleocytosis; or</li> <li>Peripheral neurologic syndromes with normal CSF (including radiculopathy, diffuse neuropathy, mononeuropathy multiplex, or cranial neuropathy) if severe or following treatment failure with oral antibiotic therapy; or</li> <li>Encephalomyelitis; or</li> <li>Encephalopathy.</li> </ul>\n<li>Meningitis; or</li>\n<li>Any neurologic syndrome with cerebrospinal fluid (CSF) pleocytosis; or</li>\n<li>Peripheral neurologic syndromes with normal CSF (including radiculopathy, diffuse neuropathy, mononeuropathy multiplex, or cranial neuropathy) if severe or following treatment failure with oral antibiotic therapy; or</li>\n<li>Encephalomyelitis; or</li>\n<li>Encephalopathy.</li>\nAnd antibiotic used is:\n<ul> <li>Ceftriaxone (Rocephin<sup>\u00ae</sup>), cefotaxime (Claforan<sup>\u00ae</sup>), or Penicillin G; or</li> <li>Azithromycin (Zithromax<sup>\u00ae</sup>) in individuals with betalactam allergy or intolerance.</li></ul>\n<li>Ceftriaxone (Rocephin<sup>\u00ae</sup>), cefotaxime (Claforan<sup>\u00ae</sup>), or Penicillin G; or</li>\n<li>Azithromycin (Zithromax<sup>\u00ae</sup>) in individuals with betalactam allergy or intolerance.</li>\nInvestigational and Not Medically Necessary:\nIntravenous (IV) antibiotic therapy for individuals with Lyme disease is considered investigational and not medically necessary when criteria are not met, including when the following IV drugs are used:\n<ul> <li>Carbapenems (for example, doripenem, ertapenem, imipenem, meropenem); or</li> <li>First-generation cephalosporins (for example, cefazolin); or</li> <li>Fluconazole; or</li> <li>Fluoroquinolones (for example, levofloxacin, moxifloxacin).</li></ul>\n<li>Carbapenems (for example, doripenem, ertapenem, imipenem, meropenem); or</li>\n<li>First-generation cephalosporins (for example, cefazolin); or</li>\n<li>Fluconazole; or</li>\n<li>Fluoroquinolones (for example, levofloxacin, moxifloxacin).</li>\nOther indications for intravenous (IV) antibiotic therapy for Lyme disease are considered investigational and not medically necessary, including, but not limited to any of the following:\n<ul> <li>Prophylactic treatment of individuals who have reported a tick bite but have no clinical findings suggestive of Lyme disease; or</li> <li>Treatment of individuals with systemic symptoms without serologic or cerebrospinal fluid (CSF) studies confirming Lyme disease; or</li> <li>Treatment of chronic fatigue syndrome or fibromyalgia attributed to Lyme disease; or</li> <li>Initial treatment of Lyme arthritis without coexisting neurological symptoms; or</li> <li>Treatment of persistent Lyme-associated arthritis after 2 prior courses of antibiotic therapy; or</li> <li>Treatment of \u201cpost-Lyme disease\u201d syndrome; or</li> <li>Repeat or prolonged courses (greater than 4 weeks) of intravenous antibiotics.</li></ul>\n<li>Prophylactic treatment of individuals who have reported a tick bite but have no clinical findings suggestive of Lyme disease; or</li>\n<li>Treatment of individuals with systemic symptoms without serologic or cerebrospinal fluid (CSF) studies confirming Lyme disease; or</li>\n<li>Treatment of chronic fatigue syndrome or fibromyalgia attributed to Lyme disease; or</li>\n<li>Initial treatment of Lyme arthritis without coexisting neurological symptoms; or</li>\n<li>Treatment of persistent Lyme-associated arthritis after 2 prior courses of antibiotic therapy; or</li>\n<li>Treatment of \u201cpost-Lyme disease\u201d syndrome; or</li>\n<li>Repeat or prolonged courses (greater than 4 weeks) of intravenous antibiotics.</li>\nIntramuscular antibiotics as a treatment of any aspect of Lyme disease are considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Intravenous (IV) antibiotic therapy for Lyme disease",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A course of up to 4 weeks of intravenous (IV) antibiotic therapy is considered medically necessary for individuals with Lyme disease meeting ANY of the following criteria:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Myocarditis associated with second- or third-degree atrioventricular block, or with first-degree heart block when the PR interval is prolonged to 300 milliseconds or greater",
                  "conditions": null
                },
                {
                  "desc": "Persistent or recurrent joint swelling (that is, arthritis) after an initial 1 month trial of oral antibiotics",
                  "conditions": null
                },
                {
                  "desc": "Acute or chronic neurological disease affecting the central or peripheral nervous system, including ANY of the following:",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Meningitis",
                        "conditions": null
                      },
                      {
                        "desc": "Any neurologic syndrome with cerebrospinal fluid (CSF) pleocytosis",
                        "conditions": null
                      },
                      {
                        "desc": "Peripheral neurologic syndromes with normal CSF (including radiculopathy, diffuse neuropathy, mononeuropathy multiplex, or cranial neuropathy) if severe or following treatment failure with oral antibiotic therapy",
                        "conditions": null
                      },
                      {
                        "desc": "Encephalomyelitis",
                        "conditions": null
                      },
                      {
                        "desc": "Encephalopathy",
                        "conditions": null
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "Intravenous (IV) antibiotic therapy for Lyme disease",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "And antibiotic used is:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Ceftriaxone (Rocephin\u00ae), cefotaxime (Claforan\u00ae), or Penicillin G",
                  "conditions": null
                },
                {
                  "desc": "Azithromycin (Zithromax\u00ae) in individuals with betalactam allergy or intolerance",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Intravenous (IV) antibiotic therapy for Lyme disease",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Intravenous (IV) antibiotic therapy for individuals with Lyme disease is considered investigational and not medically necessary when criteria are not met, including when the following IV drugs are used:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Carbapenems (for example, doripenem, ertapenem, imipenem, meropenem)",
                  "conditions": null
                },
                {
                  "desc": "First-generation cephalosporins (for example, cefazolin)",
                  "conditions": null
                },
                {
                  "desc": "Fluconazole",
                  "conditions": null
                },
                {
                  "desc": "Fluoroquinolones (for example, levofloxacin, moxifloxacin)",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Intravenous (IV) antibiotic therapy for Lyme disease",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Other indications for intravenous (IV) antibiotic therapy for Lyme disease are considered investigational and not medically necessary, including, but not limited to any of the following:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Prophylactic treatment of individuals who have reported a tick bite but have no clinical findings suggestive of Lyme disease",
                  "conditions": null
                },
                {
                  "desc": "Treatment of individuals with systemic symptoms without serologic or cerebrospinal fluid (CSF) studies confirming Lyme disease",
                  "conditions": null
                },
                {
                  "desc": "Treatment of chronic fatigue syndrome or fibromyalgia attributed to Lyme disease",
                  "conditions": null
                },
                {
                  "desc": "Initial treatment of Lyme arthritis without coexisting neurological symptoms",
                  "conditions": null
                },
                {
                  "desc": "Treatment of persistent Lyme-associated arthritis after 2 prior courses of antibiotic therapy",
                  "conditions": null
                },
                {
                  "desc": "Treatment of \u201cpost-Lyme disease\u201d syndrome",
                  "conditions": null
                },
                {
                  "desc": "Repeat or prolonged courses (greater than 4 weeks) of intravenous antibiotics",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Intramuscular antibiotics as a treatment of any aspect of Lyme disease",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Intramuscular antibiotics as a treatment of any aspect of Lyme disease are considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 3368,
          "prompt_tokens": 2229,
          "completion_tokens": 1139,
          "total_cost": 0.028229999999999998,
          "processing_time": 16.5567889213562
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e001731.html",
    "subject": "Electrical Impedance Scanning for Cancer Detection",
    "document_number": "MED.00139",
    "publish_date": "06/28/2023",
    "status": "Reviewed",
    "last_review_date": "05/11/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Electrical impedance scanning for cancer detection is considered <strong>investigational and not medically necessary</strong> for all indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nElectrical impedance scanning for cancer detection is considered investigational and not medically necessary for all indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Electrical impedance scanning for cancer detection",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Electrical impedance scanning for cancer detection is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 911,
          "prompt_tokens": 839,
          "completion_tokens": 72,
          "total_cost": 0.005275,
          "processing_time": 1.5206048488616943
        }
      }
    ]
  }
]